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Preface 
This study contains two parts, part I and part II. 
Part I consists of a review over current diagnostic methods and the ongoing intense search to find 
ideal biomarkers which possibly can be used in the detection of certain pregnancy complications, such 
as pre-eclampsia and IUGR. This part is based on the most current literature regarding this issue. We 
have also used some old articles since these contain basic knowledge.    
Part II is a pre-study where we have tried to extract total mRNA from whole blood and use real-time 
PCR to quantify certain feto-placental mRNA transcripts in the whole blood of pregnant women. The 
first and second part of the study can be read separately, dependent on the reader’s aim.  
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Abstract 
Pre-eclampsia and Intrauterine Growth Restriction (IUGR) are pregnancy-related diseases. Pre-
eclampsia is diagnosed by the presentation of proteinuria with hypertension or proteinuria alone. 
Diagnosis of IUGR is based on ultrasonic fetal size measurements in the first trimester. Fetal DNA and 
mRNA circulate in the maternal plasma and, as recently suggested, also in maternal whole blood. 
Altered levels of several fetal mRNAs have been associated with pre-eclampsia and IUGR. Thus, 
circulating fetal mRNA could be a possible biomarker for use in the pre-symptomatic diagnosis of 
these diseases.  
Through a literary study we have aimed to identify fetal mRNA transcripts expressed specifically in the 
placenta and/or fetus. Based on their potential suitability, -hCG, HLA-G and CRH were selected for the 
aim of further investigations regarding pre-symptomatic diagnosis of the mentioned conditions. We 
have tried to clarify this through literary and experimental work.  
Messenger-RNA transcripts in whole blood have been suggested as a better alternative to 
plasma/serum mRNA because of higher sensitivity with regards to RT-PCR amplification. We have in 
our pre-study shown that GAPDH mRNA can be extracted and quantified using rtRT-PCR from whole 
blood.  
Another aim of this study was to recommend a kit most suitable for RNA purification and RT-PCR 
amplifications. 
Based on our results, -hCG is the most highly recommended transcript for further studies, since high 
concentrations of -hCG are found during the first trimester. In our case, the “Purelink Total RNA 
Blood Purification” kit from Invitrogen was the most successful for the aim of total RNA extraction 
from whole blood. 
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Introduction  
Pre-eclampsia and Intrauterine Growth Restriction (IUGR) are conditions linked to pregnancy. So far 
the diagnosis of the two conditions has only been possible by continuous measurements and 
monitoring for symptoms throughout the last half of the pregnancy.  
It is if interest to early in pregnancy, before the symptoms establish, to clarify if the fetus is at high risk 
of developing IUGR or a pre-eclamptic state will occur. However, this is not possible at present. If one 
could point out those pregnancies already in the end of the first trimester, where an increased risk of 
getting these pregnancy complications later in gestation is present, it would be possible to monitor 
these women more closely. Some day it might even be possible to treat these women. Therefore a 
method of diagnosing pre-eclampsia and IUGR early in gestation is needed  
In recent years it has been discovered through various studies that free fetal RNA and DNA can be 
detected in the maternal blood of the pregnant women, as early as in the first trimester of the 
pregnancy. Some of the fetal mRNA transcripts are interesting as they may be specific fetal mRNA-
transcripts only expressed in the placenta, and not usually found in the blood of non-pregnant women. 
This is interesting as these transcripts might be useful as biomarkers in the diagnosing of various 
pregnancy disorders.  
Several studied have already shown that levels of certain mRNA transcripts increase markedly in the 
blood circulation of women suffering from pregnancy-associated complications such as pre-eclampsia 
and IUGR.   
 
This project is a pre-study to obtain important knowledge that may form the basis for further 
experimental studies because in the given amount of time we will not be able to determine whether or 
not the fetal mRNA transcripts can be used as biomarkers in the diagnosis of pre-eclampsia and IUGR.  
The following objectives are defined for the project: 
 
 The primary objective is to try to identify mRNA transcripts specifically expressed in the placenta 
and /or fetus and investigate if some of these potentially can be involved in the pathophysiology 
of pre-eclampsia and IUGR through the study of literature.  
 
 So far the focus has been on free fetal mRNA in maternal serum/plasma. However newer studies 
indicates that total RNA from whole blood gives a better sensitivity in the real-time RT-PCR used 
to amplify feto-placental mRNA-sequences. Therefore another aim in this study is to either verify 
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or disprove if this is the case looking a specific mRNA transcripts, and furthermore to investigate 
if various dilutions of extracted RNA have an impact on the final results.  
 
 A last objective is through literary and experimental studies to investigate which RNA purification 
kits can be recommended the extraction of RNA from the whole blood, and which type of real-time 
PCR (one-step or two-step) method would be most efficient to use for the given purpose.  
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1 Part I: Review  
1.1 Pre-eclampsia  and Intrauterine Growth Restriction (IUGR) 
1.1.1 Pre-eclampsia  
The term pre-eclampsia is originally a Greek term which means, “like a flash of light” (Llewellyn-Jones 
et al., 1986). This term was given due to the sudden and severe occurrence of pre-eclamptic sickness, 
which was believed to occur without any sign of symptoms previous to illness. Despite many centuries 
of research focusing on the cause of pre-eclampsia, there does not to exist a definitive pathological 
definition of this sickness (Reviewed by Sibai et al., 2005; Reviewed by Hviid and Hviid, 2000). 
Pre-eclampsia effects between 2-7% of all pregnancies, although these numbers can differ as 
definitions of pre-eclampsia can vary in different countries (Reviewed by Sibai et al., 2005; Reviewed 
by Hviid and Hviid, 2000). Also the percent of women affected by pre-eclamptic symptoms may be 
higher in less developed countries (Reviewed by Sibai et al., 2005). This might be due to less efficient 
medical care, where the necessary resources needed to check for symptoms throughout the entire 
pregnancy are not available. Regular check-ups throughout pregnancy are necessary since 
physiological changes causing a mild case of pre-eclampsia to develop into a severe case can happen 
abruptly (Cunningham et al., 1997). 
 
1.1.1.1 Risk Factors 
There is much debate as to the actual risk factors involved in pre-eclampsia and many groups thought 
of as being at risk are believed to be so based on a certain theory (Reviewed by Sibai et al., 2005). 
Some of these theories are better documented then others, although necessary when designing a 
research project in order to investigate the illness further.  
It is widely accepted that women under 20 years of age (Reviewed by Sibai et al., 2005) or those over 
35 are of a higher risk group. Also nulliparous women are more prone to develop pre-eclampsia then 
multipara women. However women that have had an earlier pregnancy involving pre-eclampsia has 
higher chances of developing pre-eclampsia in the second pregnancy also Another risk factor can be 
prolonged intervals between pregnancies, obesity, or genetic background (Reviewed by Sibai et al., 
2005). 
The reasons for these being groups of particularly high risk are more or less empirically based. Some 
theories focus on the importance of the fetus being exposed to semen from the father, and not another 
partner. Exposure is of importance both before gestation, and throughout the entire pregnancy. This is 
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believed to be of importance in inducing certain immune responses under gestation (Reviewed by 
Sibai et al., 2005; Reviewed by Hviid and Hviid, 2000). This is also why it is believed that younger 
women who become pregnant without having a steady partner may be more prone to the 
development of pre-eclamptic symptoms (Reviewed by Sibai et al., 2005). 
It has also been documented that men who have fathered pre-eclamptic pregnancies with one woman 
may have the same result for a pregnancy with another woman (Reviewed by Sibai et al., 2005). The 
new partner has only a slightly higher risk of developing pre-eclampsia than the background 
population of women, however. Knowledge as to the functioning genetic and immunological role 
between mother, fetus and father is relatively vague and in need of more research (Reviewed by Hviid 
and Hviid al., 2000). It is also suspected that women who have a history of pre-eclampsia in their 
family may be more predisposed. There are varying ideas as to which genes might be relevant to 
identify when diagnosing pre-eclampsia (Reviewed by Sibai et al., 2005; Cunningham et al., 1997).  
Obesity is welldocumented to predispose women to pre-eclampsia. Women who are obese in 
pregnancy are especially prone to insulin resistance, which also seems to be a contributing factor to 
pre-eclampsia (Reviewed by Sibai et al., 2005).  
 
1.1.1.2 Characteristic symptoms of pre-eclampsia 
Pre-eclampsia is generally characterized by pregnancy induced hypertension together with protenuria 
(Reviewed by Sibai et al., 2005; Llewellyn-Jones et al., 1986; Cunningham et al., 1997). Pre-eclampsia 
can be complicated to predict based on the above criteria as the illness can exist very early in a 
pregnancy, even if signs of hypertension and/or protenuria first become evident much later 
(Cunningham et al., 1997). However, hypertension can seize to exist in the pregnant woman without 
developing her developing pre-eclampsia (Cunningham et al., 1997).  
Proteinureia, where high levels of protein are found in the urine of pregnant women is due to 
glomerular lesions (Cunningham et al., 1997).  Such lesions may come as a result of hypertension, 
since hypertension can have vascular effects on patients. Glomerular lesions can, in severe cases, 
result in decreased renal blood flow, and in worst cases renal failure. Symptoms of hypertension can 
also exist long before signs of proteinuria become evident (Llewellyn-Jones et al., 1986).  Even without 
signs of proteinuria, patients with severe cases of hypertension must be treated and monitored 
throughout their pregnancy, as this can have serious effect for the health and mortality of both mother 
and fetus (Cunningham et al., 1997).  It is important to monitor the blood pressure of women 
throughout the entire pregnancy, especially from the beginning in order to compare with blood 
pressure later in the pregnancy. Blood pressures naturally fall in the second and early third trimester 
this is true for both normotensive as well as hypertensive women (Cunningham et al., 1997).  
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Hypertension can exist in patients before pregnancy, or be induced by gestation in both cases long 
term hypertension can lead to cardiovascular deterioration (Cunningham et al., 1997). 
There are many other symptoms involved with determining pre-eclampsia. The diagnostic methods 
will be defined more closely in the following section of this report. It is important to note that despite 
the knowledge of these existing symptoms, there still exists a large measure of doubt when predicting 
and defining pre-eclampsia in patients. Many of the symptoms observed in pre-eclamptic patients can 
be unstable to use as an indicator of sickness, since one or more symptoms can or cannot exist at the 
same time, despite registered pre-eclampsia. 
 
1.1.1.3 Cause of sickness  
Pre-eclampsia has previously been thought of as being due to poor placentation. This is no longer the 
general understanding, although this illness is in some way is found to be involved with the actual 
presence of the placenta in the mother. In some way a lack of symbioses between mother and fetus 
exists, where the placenta does not initiate the proper responses from one or the other. 
The development of human placentation is extremely invasive. Cytotrophoblast cells along with 
syntiotrophoblast cells create the outlining blastocoel. The cytotrophoblast cells make the invasion 
into the uterine wall. This invasion affects the mucosal lining of the endometrium, which becomes the 
decidua during gestation (Langman, 1981). Different types of endothelial and nervous tissue are 
destroyed under such invasion, where the job of endovascular cytotrophoblast cells is to replace the 
tissue of spiral arteries in the myometrium. The replacement of this tissue is part of the process in 
providing stable blood vsculature to the fetus, under the whole of gestation (Reviewed by Sibai et al., 
2005).   
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Figure 1.1.1.1: This figure shows anatomy of an implantet blastocyst at 10 days (A) and at 12 days (B) 
after fertilization (Cunningham, 2005). 
 
This vascular stability is important as the increased blood flow of the mother under gestation must be 
controlled through the new regulating blood vessels, so as to not have a negative impact on the fetus, 
which must have a more constant blood flow. A lack of blood flow can also result in hypoxia, which can 
influence the release of different insulin-related growth factors (Reviewed by Sibai et al., 2005). 
Vascular and other invasive physiological changes under gestation might result in a natural and 
necessary inflammatory condition within the uterus. Necessary immune responses seem to occur as a 
reaction to the inflammatory condition in the mother. Complications may arise when inflammation 
becomes too violent, or when the correct immunological responses do not occur (Reviewed by Sibai et 
al., 2005). 
The trophoblast invasion into the uterine wall triggers a massive invasion of leucocytes and most 
importantly natural killer cells. There may be a close connection in the vascular and immunological 
responses that occur under gestation. Natural killer cells within the uterus produce several cytokines, 
some of which are readily involved in angiogenesis and thereby vascular stability. There are many 
proteins expressed by certain cytokines which seems to be found significant decreased in cases of pre-
eclampsia as a result of failed immune responses to the inflammatory condition under gestation 
(Reviewed by Sibai et al., 2005). Furthermore, there seems to be a correlation between the expression 
of certain proteins by and on the trophoblast cells and the risk of developing pre-eclampsia. Antigens 
such as HLA-G are expressed by cytotrophoblast cells and seems to be involved in both activation and 
release of natural –killer cells and at the same time being responsible for certain endovascular changes 
(Reviewed by Hviid and Hviid, 2000). 
There are many theories asserting that when vascular or immunological changes under gestation 
malfunction at some level or other, it will most likely result in pre-eclampsia. It is not necessarily 
cytotrophoblast cells alone which can be of interest when investigating pre-eclampsia. Under normal 
gestation there is a concentration of syntiotrophoblast cells which are shed, afterwards migrating into 
the mother’s blood. In cases of pre-eclampsia, the levels of syntiotrophoblast cells shed are much 
higher, than concentrations found under normal pregnancies. These high concentrations of 
syntiotrophoblast cells can result in a greater and thereby also dangerous inflammatoric response in 
the mother. This may or may not be followed by the natural immunological responses otherwise 
induced by the uterine inflammatoric condition (Reviewed by Sibai et al., 2005). 
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1.1.2 Intrauterine Growth Restriction (IUGR)  
When size of a fetus is less than expected from its gestational age it is defined as Small for Gestational 
Age (SGA). Battaglia & Lubchenco classified in 1967 SGA as those infants whose birth weight was 
below the 10th percentile for the gestational age, and ever since this limit has been used as a diagnostic 
measurement for SGA. However, it should be noted that some fetuses can be growth restricted even 
though they are above this limit. 
SGA is divided into two subgroups, where one of them is, when the fetus grow normally in the uterus 
but is constitutionally small (Reviewed by Peleg et al., 1998; Reviewed by Brodsky and Christou, 
2004). This type of growth restriction is usually genetically determined according to geographic 
location, ethnic group and the inherited maternal genes in general (Cunningham et al., 1997; Reviewed 
by Neerhof, 1995). The other group is where the fetus is smaller due to fetal and maternal pathological 
conditions and the fetus does not reach its appropriate growth potential (Reviewed by Peleg et al., 
1998).  These fetuses are diagnosed with Intrauterine Growth Restriction (IUGR). 
 
IUGR occurs in 3-10% of all pregnancies and is divided into symmetrical- and asymmetrical growth 
restriction depending on when in the pregnancy the impaired fetal growth occurs. If the growth 
restriction appears during the first or second trimester, the infant will have a symmetrical growth 
restriction.  The infant has a proportionate reduction in growth due to reduced fetal cell proliferation 
in all organs.  On the contrary, if the growth restriction occurs in the third trimester, the infant has an 
asymmetrical growth restriction and the abdominal size will be smaller compared to the size of the 
head (Reviewed by Brodsky and Christou, 2004).   
This asymmetrical growth impairment is the most common and happens to approximately 70-80% of 
all IUGR infants, whereas the symmetrical growth restriction only occurs in 20-30% of the cases.  The 
latter gives a greater risk of morbidity and mortality. 
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1.1.2.1 Risk factors and cause of sickness 
In general IUGR occurs as a result of malnutrition of the fetus. Many different parameters play an 
important role in the disorder and some of these are listed in table 1.1.2.1below. The causes and risk 
factors in IUGR are very similar or practically the same as in pre-eclampsia and therefore they will not 
be further discussed in this section. The most common cause of this disorder in the Western countries 
is placental insufficiency. However the main cause of fetal growth impairment in the developing 
countries is maternal malnutrition and malaria (Menendez et al., 2000). 
Some Causes and risk factors of Intrauterine Growth Restriction 
Maternal Placental Fetal 
Diseases: 
- Hypertension 
- Diabetes Millitus 
- Renal disease 
- Pulmonary disease 
- Cardiovascular disease 
- Severe Anemia 
- Antiphospholipid Antibody 
Syndrome 
- Pre-eclampsia 
 
Other causes: 
- Undernutrition 
- Substance abuse (tobacco, 
alcohol, drugs) 
- Malformations 
- Irradiation 
- Prepregnancy weight and 
weight gain during pregnancy 
   
Placental insufficiency: 
- Abnormal 
trophoblast invasion 
 
Abnormal placentation: 
- Placenta praevia 
- Placental infarcts 
- Umbilical-placental 
vascular anomalies 
 
 
Genetic predisposition: 
- Chromosomal abnormalities 
(Trisomy 13, 18, 21) 
- Turner’s Syndrome 
- Family history 
 
Intrauterine Infections: 
- Rubella 
- Herbes 
- Toxoplamosis 
- Malaria 
- HIV 
- Cytomegalovirus 
 
Other causes: 
- Multiple Gestation  
 
Table 1.1.2.1: The table shows some causes and risk factors of Intrauterine Growth Restriction 
(Modified from Peleg et al., 1998; Brodsky and Christou, 2004; Haram and Gjelland, 2007). 
 
In general one can divide the occurrence of IUGR into  three scenarios that separately or together give 
rise to a growth restricted state of the fetus: abnormal placental function, inadequate maternal supply 
of oxygen and/or nutrients, and/or because the fetus lacks the ability to use the supply it is given.   
As noted in the earlier section 1.1.1, pre-eclampsia is characterised by shallow cytotrophoblast 
invasion of the uterus and abnormal differentiation of these cells. This leads to deficient perfusion and 
local placental hypoxia, which often gives rise to IUGR because of fetal nutrient insufficiency. 
Moreover, there has been observed an increased rate of apoptosis of the trophoblast cells in IUGR, 
which also prevent the placenta from carrying out its normal function (Kingdom et al., 2000).  
Furthermore, oxidative stress, placental infarctions, cytokine damage and hypertension, give rise to an 
abnormal placental function and malnutrition of the fetus; thereby these factors also have influence on 
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the fetus’ growth restriction (Kingdom et al., 2000). These factors are also seen in many pre-eclampsia 
cases but not in all.  
Another pathway that might contribute to fetal growth restriction as well is insulin and the associated 
insulin-like growth factors (IGF)-1 and -2. These are the most essential hormones in fetal growth. Thus 
it is argued that these hormones might have an important role in the occurrence of IUGR (Fowden, 
2003). Additionally, there have also been indications of alteration in the gene expression or activity of 
placental transporters which might have a crucial role in the fetal growth impairment, especially the 
amino acid transporters (Jansson and Powell, 2000). 
The outcome of fetal growth restriction depends on the severity of the growth restriction and the 
etiology of the disorder. Some children have an increased growth within the first 3 years, whereas 
some, about 10%, will have persistent growth problems (Lee et al., 2003). Depending on the severity 
of the disorder the child can, for instance, suffer from neurotical disabilities, impaired renal function, 
increased susceptibility to infection and growth hormone defiency and abnormalties of IGF-1, fasting 
insulin glucose and lipid levels (Lee et al., 2003; Simchen et al., 2000; Ojeda et al., 2008). In the later 
adulthood hypertension, type 2 diabetes, and coronary artery disease can occur. 
 
Both pre-eclampsia and IUGR cannot be cured or directly treated. In some pre-eclampsia cases, where 
hypertension is a problem, one can administer antihypertension medication but this will not change 
the progression of the disorder. Nor will it prevent or reverse IUGR if this is part of the pre-eclamptic 
state (Reviewed by Brodsky and Christou, 2004).  In IUGR numerous attempts to improve the growth 
patterns has been performed but so far none has been effective. Frequent monitoring of the pregnant 
woman is necessary in both pre-eclampsia and IUGR and hereby the safest time for delivery can be 
determined. Determination of the time of delivery depends on the fetus’ state, maternal health and the 
severity of pre-eclampsia or/and IUGR.  
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1.2 Current diagnostic methods  
1.2.1 Current diagnostics methods of pre-eclampsia  
The most important symptom of pre-eclampsia is proteinuria. Chesley (1985) concluded that the 
diagnosis preeclampsia, in absence of proteinuria is doubtful.  
Pre-eclampsia is defined, based on the presence of protein in the pregnant woman’s urine. Three 
hundred mg/L or more proteinuria measured within 24 hours in at least two randomly, five hours 
apart, urin samples. Hypertension is defined as blood pressure surpassing 140/90 mmHg, if the blood 
pressure surpasses 160/110 mmHg it is considered as severe. 
The degree of proteinuria can vary much in a 24 hour period, even in cases with severe pre-eclampsia. 
Hence, for validation of the diagnosis, at least two urine tests must be performed. McCartney et al. 
(1971) conducted an extensive study of renal biopsies from hypertensive pregnant women. This study 
showed a clear link between the presence of proteinuria and preeclampsia. Proteinuria and alteration 
of glomerular histology is seen late in pregnancy-induced hypertension. In the absence of proteinuria, 
pre-eclampsia can be diagnosed, when hypertensive patients also show signs of persistent cerebral 
symptoms, nausea or vomiting and/or thrombocytopenia and abnormal levels of liver enzymes. The 
criteria mentioned above does not apply for women that suffer of either hypertension or proteinuria 
before the 20 weeks gestation.  
 
Friedman and Neff (1976) reported an association of hypertension with fetal death rate. Pregnant 
women with hypertension, defined as a diastolic blood pressure of 95 mmHg or more, have three 
times increased risk of fetal death compared with women experiencing normal pregnancy. The study 
also shows that the most increased fetal death rates occur among women suffering from hypertension 
combined with proteinuria, whereas the women only suffering from proteinuria, move the statistics 
only slightly towards an increased fetal death rate. Naeye and Friedman (1979) concluded that around 
70 percent of the excess fetal deaths among the same group of women were due to enlarged placental 
infarcts and significant contracted placenta. 
 
Chesley (1985) pointed out that around 10 percent of all pre-eclamptic outbursts indeed develop 
before the apparent proteinuria. Therefore, from the pathophysiological and epidemiological point of 
view, it is clear that hypertension is a crucial factor in diagnosis of pre-eclampsia. When blood 
pressure surpasses 140/90 mmHg, pregnancy-induced hypertension is diagnosed and the mother 
ought to be treated for her condition. Proteinuria is seen when the hypertensive disease is worsened, 
namely pre-eclampsia, and when the condition is visible and prolonged, maternal and fetal fatality 
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risks are heightened significantly, especially among first time pregnant compared with multipara 
(Reviewed by Hviid and Hviid, 2000).  
For an overall view of the definitions of pre-eclampsia, see below:  
 
1.2.2 HELLP-syndrome 
Another condition associated with pre-eclampsia is the so-called HELLP-syndrome.  Patients 
with HELLP-syndrome suffer of haemolysis, elevated liver enzymes, ALAT/ASAT and have 
low platelets (Johansen et al., 2001; Skajaa et al., 2003). For an overall view of the definitions 
of pre-eclampsia indications see below;   
Proteinuria 300 mg/l or more pr. 24 hour detected x 2, 5 
hours apart 
Blood pressure/Hypertension Mild:140/90mmHg  
Sever: 160/100 mmHg 
HELLP-syndrome Enzymes ALAT/ASAT 100U/l Low platelets 
<100 x 10^9/l  
Proteinuria 300 mg/l or more in at least two urin samples, 
taken h hours apart within 24 hours 
Blood pressure/Hypertension Mild: 140/90mmHg  
Severe: 160/100 mmHg 
 
Fetal mRNA in maternal whole blood                        6/5/2008 
 
 17 
1.2.3 Current diagnostics methods in IUGR  
In the diagnoses of IUGR knowledge of the fetal size is the most essential. As the growth rate and 
thereby size of the fetus should lie within the same range for all normal pregnancies, another very 
important part is accurate determination of the gestational age (IUGR, 2008). The gestational age is 
mainly determined by various first trimester ultrasonic measurements (GSA ultrasound, 2008). 
There are several more or less accurate methods that can be used to determine the fetal size.  
 
1.2.3.1 Uterine fundal height measurements 
The easiest and most inexpensive method of fetal size determination is uterine fundal height 
measurements performed continuously throughout the pregnancy (Cunningham et al., 1997). Even 
though this method is not the most accurate one, it is still important in clinically frontline-evaluation of 
IUGR (Cunningham et al., 1997).  
 
1.2.3.2 Ultrasonic size measurements  
The most commonly used method for determination of fetal size is based on ultrasonic measurements 
of the fetus (IUGR, 2008). From such measurements the estimated fetal weight (EFW) is determined, 
wherefrom IUGR can be diagnosed.  
There are several different measurements that can be done, but the abdominal circumference (AC) is 
accepted as the most consistent index of fetal size (Cunningham et al., 1997).  
 
1.2.3.3 Doppler blood flow measurements 
Doppler velocimetry, which is based on the Doppler principle in ultrasonic measurements, can be used 
to determine the velocity of red blood cells within the arteries during the systolic and diastolic phase 
of the cardiac cycle. Decreasing, absent or reversed diastolic blood flow can be an indication of 
worsening IUGR (Iame, 2008). 
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1.3 Fetal DNA and mRNA in maternal plasma/serum and whole blood 
1.3.1 Fetal DNA and mRNA 
Cell-free feto-placental DNA and mRNA circulate in maternal blood during pregnancy (Crowley et al., 
2006). The presence of mRNA, DNA and placenta cells has been shown to be increased during 
pregnancy (Bianchi, 2004). However sometimes dramatic changes in the concentration of these are 
seen and have been hypothesized to be associated with pre-eclampsia and IUGR.  Furthermore, a 
number of studies have shown apart from DNA, RNA is also circulating in the blood plasma of 
individuals carrying various disorders, especially cancer (Ng et al., 2003A).  
At present it is difficult to diagnose pre-eclampsia or IUGR before the symptoms establish as there is 
no method developed yet to foresee these disorders. Hence, the finding of fetal DNA and RNA in 
maternal blood is of particular relevance. By using specific fetal DNA and RNA it might be possible to 
detect certain courses of gestation that might have increased risk of developing pre-eclampsia or IUGR. 
Furthermore, it might give a better diagnosis of the different variants of these complications. Finally, 
these markers will provide further insight of the pathogenesis and the pathological mechanisms of 
pre-eclampsia and IUGR (Cotter et al., 2004). 
The passage of fetal mRNA, DNA and sub-cellular particles into maternal blood circulation is 
hypothesised to be decisive for development of proper maternal immune response to the feto-
placental unit. Fetal DNA, mRNA and placental cells enter the maternal blood circulation by different 
mechanisms. Syncytiotrophoblast cells secrete among other hormones, human chorionic 
gonadotrophin (hCG) (Islami et al., 2001; Staun-Ram and Shalev, 2005), which have been shown to 
circulate in the plasma and whole blood (Okazaki et al., 2005). The volume of the trafficked units does 
not neccesarily correlate with fetal DNA (Hahn et al., 2005). Interestingly, fetal erythroblasts, placental 
syncytiotrophoblast microvesicles and fetal DNA have been measured at higher concentrations in pre-
eclamptic pregnant women (Holzgreve et al., 1998; Chua et al., 1991; Lo et al., 1999). Furthermore, 
increased cellular (Al-mufti et al., 2000a) and cell free fetal DNA, fetal trafficking is seen before the 
symptoms of these conditions appear (Leung et al.,2001; Zhong et al.,2002; Levine et al.,2004). 
 When IUGR is established, increased trafficking of fetal erythroblasts are seen (Al-Mufti et al., 2000b) 
but there are contradictory reports as to whether or not cell free fetal DNA is increased in this disorder 
(Smid et al., 2001; Sekizawa et al., 2003). Additionally, changes in cellular trafficking may forego in the 
development of IUGR (Al-Mufti et al., 2000a).  
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1.3.2 Fetal DNA: The Limitations 
It could seem as quantification of fetal DNA in maternal blood would be a favourable method in 
screening for pregnancy disorders but there are certain limitations in half of all the pregnancies. Fetal 
DNA in maternal plasma carries the Y chromosome-specific gene sequences. These sequences are used 
as fetal markers in pregnant women carrying a male offspring (Okazaki et al., 2005). Usage of Y 
chromosome-specific sequences assures additionally differentiation between the fetal DNA and 
maternal DNA; this also puts a limit for the usability of the under-developing screening methods(Ng et 
al., 2003A).Cell free fetal DNA is released into maternal blood during maternal and/or fetal cell 
necrosis/apoptosis or both mechanisms. (Bisschoff et al., 2005). DNA is primary used to detect 
polymorphism and mutations in the genes, while mRNA contains important information about the 
current molecular activity in the placenta. It has been hypothesised and shown by many studies that 
certain gene sequences' level is altered during pre-eclampsia compared with uncomplicated 
pregnancies. Elevated levels of fetal and maternal DNA gas been detected in maternal plasma(Lo et al., 
1997). Increased concentrations of circulating extracellular DNA in maternal plasma may indicate 
correlation with pre-eclampsia (Review by Tjoa  et al., 2004). The release of the cell-free DNA 
originates from the programmed cell death. It has been In section 2.2.12 many relevant genes will be 
described.  It has been shown that fetal DNA levels in maternal plasma are elevated prior to onset of 
pre-eclampsia in the first trimester in women destined to develop pre-eclampsia(Leung et al., 2001; 
Zhong et al., 2002).  
 
1.3.3 Fetal mRNA in plasma/serum and maternal whole blood  
Many studies have shown the occurrence of placental mRNA in maternal blood circulation. The natural 
lability of circulating RNA in the maternal plasma may be counteracted and stabilized in the apoptotic 
bodies (Ng et al., 2003A).  
The mRNA extracted from plasma/serum is free mRNA, while the mRNA extracted from whole blood is 
“bounded” in trophoblast cells. 
There are three different suggestions on how fetal cell free mRNA ends up in the maternal circulation 
(reviewed by Hahn et al., 2004). The first suggestion is considered as the traditional way and this is by 
apoptotic release (Huppertz et al., 2003, Huppertz et al. 2001). The second way is by accidental 
breakage or necrosis of the cells, this is probably the main source of cell free mRNA (Black et al., 2004). 
The third way is by the recently defined aponecrosis. In aponecrosis incomplete execution of apotosis 
followed by breakdown of the cells as in necrosis releases cell free fetal mRNA.  
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The fetal mRNA in whole blood is observed in extravillus trophoblast cells that invade uterine tissue 
and replaces endothelial cells in the spiral arteries. These endothelial trophoblast cells may end up in 
the maternal blood circulation (Oudejans et al., 2003; Hunt et al., 2000). In the study by Okazaki et al. 
(2006), mRNA of a placental specific gene PLAC-1 (placental factor-1) was detected in the whole blood 
from pregnant women.  Due to the unusually high levels of the PLAC-1 mRNA in the whole blood 
compared to levels in plasma it was concluded that some of the PLAC-1 mRNA in the whole blood may 
stem from the cellular components in the whole blood (Okazaki et al., 2006). 
 
1.3.4 Fetal mRNA in plasma/serum 
In year 2000 Poon et al. was the first to discover the presence of mRNA in maternal plasma/serum. 
Like it is the case with DNA, detection of mRNA in maternal blood is not dependent on gender, 
placental polymorphisms or alternative detection techniques, therefore much excitement rose in the 
scientific society.  
The fetal mRNA transcripts are detectable in the maternal blood from the 4’th week of gestation (Chiu 
et al., 2006) 
In difference from DNA the level of total mRNA seems to be constant during pregnancy (Tjoa et al., 
2006), but it was in 2003 proven by Sekizawa et al. that individual mRNA levels vary throughout 
gestation. 
In most of the studies we have been reading the source of mRNA has been plasma/serum; only three of 
the studies has been dealing with plasma extracted from whole blood (Maron et al., 2007; Okazaki et. 
al. 2006; Farina et al., 2006). Out of these three studies the studies done by Maron et al. and Okazaki et. 
al. were studies comparing the level of mRNA in maternal whole blood and plasma/serum.  
All of the studies done on plasma/serum good results regarding the RNA purification was obtained. 
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1.3.5 Fetal mRNA in maternal whole blood  
There are two possible sources of fetal mRNA in the maternal blood flow, these are fetal hematopoitic 
cells and placental trophoblast cells whereof the major part of the mRNA origins from the trophoblast 
cells (Maron et al., 2007).  In the majority of the studies, we found the mRNA’s in blood plasma was the 
ones studied the most. Recent studies have shown that mRNA levels of the genes PLAC1 (Farina et al., 
2005), β-hCG, and hPL seems to be higher in the cellular component of whole blood than in the plasma 
(Okazaki et al., 2006). 
Okazaki et al.’s (2006) study compared the concentration of hPL and β-hCG in cellular and plasma 
components of maternal blood. To perform the study, 155 blood samples were obtained from 
pregnant women. They found that the overall levels of both hPL - and β-hCG mRNA were significant 
higher in maternal whole blood during all three trimesters when compared to the same sequences in 
the maternal plasma, 22.9 fold and 4.3 fold for hPL and β-hCG, respectively.  Additionally, they could 
conclude that the concentration of β-hCG transcript peaked early in pregnancy and decreased 
continuously as the pregnancy progressed.  
Even though Okazaki’s evidence seems convincing, another team of reasearcers, Maron et al. (2007), 
have also studied the concentration of various placental expressed gene transcripts in plasma 
compared to the same transcripts in the cellular component of blood. They concluded the contrary of 
Okazaki et al. (2006); Applying blood samples from nine women in the 36th week of gestation or later, 
their studies indicated that the amount of 50 previously identified placental expressed genes were 
higher in the plasma compared to whole blood both antepartum, postpartum, and in the umbilical 
cord. In fact, they found that no transcript whatsoever originating from the placenta in the cellular 
component of the maternal blood.  
A possible cause of why no placental transcripts were observed could be due to the fact, that the blood 
samples were collected from women being relatively advanced in pregnancy. 
 If we instead of looking at the overall -hCG level in Okaszki et al.’s (2006) study look at the third 
trimester level of -hCG, we see that the level in plasma is significantly higher than in whole blood. 
This indicates, at least with regard to -hCG, that the collection of blood samples from late gestation 
might be the reason why no -hCG could be detected in the whole blood in the study by Maron et al. 
(2007). Since no hPL, CRH or -hCG mRNA levels were detectable in the maternal whole blood and as 
levels of hPL mRNA in the whole blood were shown to increase in late gestation by Okazaki et al. 
(2006) a significant error might have occurred during Maron et al.'s mRNA extraction procedure. 
Furthermore, the fact that Maron et al. (2007) did not detect any hPL, CRH or hCG  is most likely due 
to extraction method. We have just been able to find these two non-consistent studies. The results 
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obtained by Okazaki et al. (2006) seem to be more accurate. However, no definite conclusion can be 
drawn at this point before further studies.  
In another study by Ng et al. (2003), obtained blood samples from six women at a gestational age of 
37-39 weeks were measured for hPL, mRNA levels in the plasma. The mean level of hPL mRNA in the 
maternal plasma was found to be 128,748 copies/mL while the mean level of hPL mRNA in maternal 
whole blood in the study performed by Antionio et al. (2006) done on 36 women at gestational age of 
11-14 weeks was found to be 1,819,748 copies/ml this gives a 14.1 fold higher level in whole blood 
compared to the plasma level of the same transcript.  
As the two studies are absolutely independent they are not fully comparable as factors such as the 
gestational age, method used in the mRNA purification, procedures connected to the real-time PCR and 
so forth, are not necessarily the same. However, as the level of hPL mRNA has been shown to increase 
throughout the pregnancy (Okazaki et al., 2006) and the level of hPL mRNA according to this study 
should be higher in the women at gestational age of 37-39 weeks compared to pregnant women of 11-
14 weeks, we believe that our assessment is somewhat reasonable.  
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1.3.6 RNA purification 
There are various different methods that can be used for purification of the RNA present in the 
bloodsamples. One of the objectives of this study was to through the literature to identify the most 
recommendable method of RNA-purification, specifically which kit and preparations that are the best 
to use for the purification.  
In everydayuse the kit’s, preoperational steps and so on, used for the diagnosis of etc. pre-eclampsia 
based on blood RNA levels has to follow a whole other and more strict set of work environmental rules 
than those that has to be followed during pilot project, furthemore it has to be an automated process. 
Therefore there are certain criteria’s that has to be fulfilled, criteria’s such as that the toxicity- and 
volatility-level of the chemicals used has to be as low as possible and that the process of the RNA-
purification has to be as simple as possible. 
Table 3 shows 7 different studies, and the different kits and procedures used for RNA-purification of 
RNA in both plasma/serum and whole blood.  
The studies shown in the table are pilot projects, and therefore the criteria’s that has to be fulfilled in 
everyday use most likely have not been considered. This means that most of the used methods will not 
be applicable to everyday use.  
As seen in the table 1.3.6.1 different containers are used for blood, these are EDTA containing tubes 
and PaxGene RNA blood tubes, which are specifically made for preserving the RNA present in blood. As 
the PaxGene tubes are made to preserve RNA one could think that the concentration of RNA in these 
samples would be higher than in the ones where blood is contained in EDTA-tubes. In the 
concentrations of hPL and βhCG in the studies by Tsui. et. al. (2004) using RNA preservatives and 
Okasaki et. al. (2006) not using preservatives there is a big difference in the first trimester level of 
βhCG, where the measured level is almost 15 fold higher in the blood with preservatives added, but if 
the difference in the βhCG-level of the third trimester is compared the level is 40 fold higher in the 
blood with no preservatives added.  
If the concentrations of first trimester hPL-levels are compared the level is the same in both studies, 
but if then the third trimester hPL-levels are compared the level is 4 fold higher in the study where 
RNA-preservatives are added to the blood. 
If it was advantageous to use RNA-preservatives the levels of both hPL and βhCG should of cause be 
higher in all cases, and as this is not the case, at least in these two studies, it does not seem like the 
RNA-preservatives have any effect on the levels of RNA in the blood. 
As shown in the table especially one kit is seen several times; the RNeasy Mini Kit (Qiagen Inc.). It is 
used in five out of the six studies done on plasma/serum (Ng et. al, Jan 2003; Maron et. al., 2007; 
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Okasaki et. al. 2006; Ng et. al 2003; Tjoa et. al. 2005) whereas the other kit represented; the QIAmp 
MinElute (Qiagen Inc.) is only used in one study (Yuditiya Purwosunu, et. al. 2007).  
All of the studies using the RNeasy Mini Kit as well as the one using the QIAamp MinElute Virus kit the 
starts the mRNA purification using Trizol and chloroform, these reagents would not be approved to 
everyday use as they are fairly toxic, and therefore, even though both the RNeasy Mini Kit and QIAamp 
MinElute Virus are fully automatable (http://www1.qiagen.com/products/automation/qiacube.aspx, 
18/05/2008), these methods would not be recommendable for RNA purification.  
All of the above mentioned methods are applied on plasma/serum samples, the last three methods 
shown in the table are used in the RNA-purification on whole blood samples.  
The two of the studies (Okasaki et. al. 2006; Tsui et. al. 2004) uses the PAXgeneTM Blood RNA kit. In 
this kit one of the reagents is the very volatile 100% EtOH, which makes these methods not 
recommendable as well, even though fairly good results are achieved and that the method is 
automatable.  
The last method used is by Farina et. al. (2006), here the ABI prism 6100 nucleic acid PrepStation 
together with the disposable starter kit is used.  Neither Trizol nor chloroform is used, but the process 
is hard to automate, so even though the results also here looks good, this method is not 
recommendable for everyday use either. 
As a conclusion we can say that none of the listed methods are really recommendable as all of them 
use very toxic reagents. The only method that might be recommendable is the ones using the 
PAXgeneTM Blood RNA kit, as no Trizol/chloroform are used in these, but still more or less the same 
toxic reagents are used in the kit so even though it is automatable and the achieved results are good, it 
would not be a recommendable for everyday use. 
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Blood 
Container 
Wholeblood 
or 
plasma/seru
m 
Preparations Kit used for 
RNA 
purification 
Reagents used for 
removal of 
contaminating 
Substances, 
mainly DNA. 
Elution fluid Analysed genes Reference 
EDTA tubes  
 
Whole blood  Applied biosystems: 
Reagents and a 
disposable starter kit 
for ABI prism 6100 
nucleic acid Prep 
Station.  
Applied biosystems:  
Absolute RNA Wash 
Solution and DNase 
treatment. 
Applied biosystems:  
Absolute RNA Wash 
Solution and DNase 
treatment. 
hPL, Inhibin A, PAPP-A 
and KISS-1 
P-Selectin, VEGF. 
Farina et al., 2006  
 
EDTA tubes  Plasma  
 
Plasma was mixed with 2 mL Trizol LS 
reagent (invitrogen) and 0,4 mL chloroform. 
Centrifuged at 11,900 g for 15 min at 4°C. 
1 vol. 700 mL/L added to 1 vol. of the aqueous 
layer and applied to the kit  (look in the next 
box) 
Qiagen Inc.: 
RNeasy Mini Kit 
 
Qiagen Inc.: 
RNase Free DNase set 
RNase-free water hPL and βhCG Ng et al., 2003a 
 
EDTA tubes  
 
Plasma  Plasma was mixed with 2 mL Trizol LS 
reagent  (invitrogen) and 0,4 mL chloroform. 
Centrifuged at 12,000 g for 15 min at 4°C. 
1 vol. 700 mL/L added to 1 vol. of the aqueous 
layer and applied to the kit  (look in the next 
box) 
Qiagen Inc.: 
QIAamp MinElute 
Virus 
  
 RNase-free water CRH, PLAC1 and  
P-Selectin 
Purwosunu et al., 2007  
 
PreAnalytiX: 
PaxGene tubes   
Whole blood   PreAnalytiX: 
PaxGeneTM Blood RNA 
kit  
Qiagen Inc.: 
RNase Free DNase set 
RNase-free water GAPDH (reference),  
DEFA1, TRBV19, MYL4 
Maron et al., 2007  
 
10 cc EDTA 
Vacutainer Blood 
Tubes. 
Plasma 600 l of plasma was mixed with 1,2 mL 
Trizol LS reagent  (invitrogen) and 0,2 mL 
chloroform. 
Centrifuged at 11,900 g for 15 min at 4°C. 
1 vol. 700 mL/L EtOH added to 1 vol. of the 
aqueous layer and applied to the kit (look in the 
next box) 
Qiagen Inc.: 
RNeasy Mini Kit 
 
Invitrogen: 
DNase 1  
RNase-free water GAPDH (reference), 
DEFA1, TRBV19, MYL4 
Maron et al., 2007 
 
EDTA tubes  
 
Plasma  Plasma was mixed with 2 mL Trizol LS 
reagent (invitrogen) and 0,4 mL chloroform. 
Centrifuged at 12,000 g for 15 min at 4°C. 
1 vol. 700 mL/L EtOH added to 1 vol. of the 
aqueous layer and applied to the  
kit (look in the next box) 
Qiagen Inc.: 
RNeasy Mini Kit 
 
 RNase-free water hPL, βhCG Okazaki et al., 2006 
 
PreAnalytiX: 
PAXgene blood RNA 
tubes 
Whole blood  
 
Centrifuged twice at 4000 g for 10 min at 
room temp.  
Pellet was washed resuspended and 
Inc.ubated in optimized buffers containing 
proteinase K to digest Proteins. 
One more centrifugation was performed to 
remove residual cell debris. 100% EtOH was 
added to adjust binding cond. And the lysate 
was applied to the column (look in the next 
box) 
PreAnalytiX: 
PaxGeneTM spin 
column  
 RNase-free water hPL, βhCG Okazaki et al., 2006 
 
EDTA tubes  Plasma  1,6 ml of plasma was mixed with 2,0 mL 
Trizol LS reagent  (invitrogen) and 0,4 mL 
chloroform. 
Centrifuged at 11,900 g for 15 min at 4°C. 
Qiagen Inc.: 
RNeasy Mini Kit 
(Ng et. Al, 2002) 
Qiagen Inc.: 
RNase Free DNase set 
RNase-free water CRH Ng et al., 2003b 
 
Fetal mRNA in maternal whole blood                        6/5/2008 
 
 26 
Table 1.3.6.1
1 vol. 700 mL/L EtOH added to 1 vol. of the 
aqueous layer and applied to the kit (look in 
the next box) 
PreAnalytiX: 
PAXgene blood RNA 
tubes 
Plasma  PreAnalytiX: 
PaxGeneTM Blood RNA 
kit 
 
Qiagen Inc.: 
RNase Free DNase set 
RNase-free water GAPDH (reference), hPL, 
βhCG , CRH 
Tsui et al., 2004 
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1.3.7 Methods used for RT-PCR  
Assessment of the different RT-PCR-methods depends on a combination of things: which kit is used, are the 
primers placed in one exon or are they spanning over more than one exon, are the primers located at an 
exon-exon transition, and at last but not least are the right controls used for elimination of amplification of 
genomic DNA instead of cDNA. 
Due to lack of time we have not been able to find the location of the primers, and thereby if they are exon-
exon spanning, exon transition spanning and so on. But still the kit used, and in some of the cases where 
the placement of the primers are described it is possible for us to try to assess the quality of the “method”.  
In table 4 five studies analyzing various genes are showed, amongst these genes are ßhCG and CRH, which 
are the ones interesting to us. Furthermore, GAPDH that we use as reference gene is somewhat interesting 
too. 
As shown in the table both one- and two-step RT-PCR are used in the studies. In the studies where two-step 
PCR are used especially the Omniscript RT Reagent kit (Qiagen inc.) is represented as the kit used for the 
reverse transcription, the other kit represented, the High-Capacity cDNA Archive kit (Applied Biosystems) 
is only used in one of the studies.  
Three different PCR-kits are represented, these are the EZ rTth RNA PCR kit (Applied Biosystems)., 
QuantiTect Probe PCR reagent kit (Qiagen Inc.) and TaqMan One-step RT-PCR Master mix reagents kit 
(Applied Biosystems). All three uses different polymerases which of cause can result in different quantities 
in the PCR process, but as all studies obtain good results regarding this it does not seem like one kit is 
better than the other. 
The applied primers and probes are probably the factor that has the biggest influence on the results. The 
probes and primers used on hPL and ß-hCG by Ng et al. (2003a) are intron spanning. Therefore the 
possibility that genomic DNA is copied instead of the wanted mRNA is very small and this makes these 
primers a good choice. The other studies where hPL and ßhCG are analyzed the primers as well as probes 
are the same as used by Ng et. al. (2003a), this also gives some kind of indication that they are good 
candidates 
In the studies including GAPDH the applied primers and probes are all the same. 
The primers and probes used by Ng et al. (2003b) and Tsui et al. (2004) for the CRH assays are the same in 
both cases as well (the same as we uses). These primers are placed in the same exon, and therefore there is 
a possibility that genomic DNA has been amplified instead of cDNA.  
In all but two studies the samples were checked for amplification of genomic DNA instead of mRNA, and in 
those not checked, contaminating DNA was removed with DNAse. The ones only removing DNA by DNAse 
and not checking for genomic DNA cannot be recommended without performing the check. Furthermore, 
studies done on HLA-G would have been interesting to look at as well, but as we were not able to find any 
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studies done on HLA-G mRNA, there were no possibility of doing this. In the experimental part of this study 
we are describing assays done on HLA-G, and in the part describing this part recommended primers and 
probes for HLA-G will be mentioned.  
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Whole 
blood 
or 
plasma/ser
um 
One-step 
or  
two-step 
PCR  
Kit used for 
reverse 
transcription 
PCR-kit Primers and probes  Analysed genes Reference 
Plasma  One-step  Applied biosystems: 
EZ rTth RNA PCR kit 
hPL:  5’-CATGACTCCCAGACCTCCTTC-3’ (forward) 
  5’-TGCGGAGCAGCTCTAGATTG-3’ (reverse) 
  5’-(FAM)TTCTGTTGCGTTTCCTCCATGTTGG- 
  (TAMRA)-3’ (probe) 
ßhCG:  5’-CTACTGCCCCACCATGACCC-3’ (forward) 
 5’-TGGACTCGAAGCGCACATC-3’ (reverse) 
 5’-(FAM)CCTGCCTCAGGTGGTGTGCAACTAC- 
 (TAMRA)-3’ (probe) 
 
hPL and ßhCG Ng et al., 2003a 
 
Whole blood  One-step  Applied biosystems· 
TaqMan One-step RT-PCR 
Master mix reagents kit. 
GAPDH:   
 5’-GAAGGTGAAGGTCGGAGTC-3’ (forward) 
 5’-GAAGATGGTGATGGGATTTC-3’ (reverse)  
 5’-(6-FAM)-CAAGCTTCCCGTTCTCAGCC- 
 (TAMRA)-3’ (probe) 
DEFA1:   
 5’-CAGCCCCGGAGCAGATT-3’ (forward) 
 5’-TTTCGTCCCATGCAAGGG-3’ (reverse)  
 5’(6FAM)CAGCGGACATCCCAGAAGTGGTTGT- 
 (TAMRA)- 3’ (probe)  
TRBV19:  
 5’-GGCCACCTTCTGGCAGAA-3’ (forward) 
 5’-AGAGCCCGTAGAACTGGACTTG-3’ (reverse) 
 5’-(6-FAM)-CCCCGCAACCACTTCCGCTG-
 (TAMRA)-3’ (probe) 
MYL4:  
 5’-GGGCCTGCGTGTCTTTGA-3’ (forward)  
 5’-CGTGCCGAAGCTCAGCA-3’ (reverse) 
 5’-(6FAM)-AAGGAGAGCAATGGCACGGTCATGG-
 (TAMRA)-3’ (probe) 
 
GAPDH, DEFA1, 
TRBV19, MYL4 
Maron et. al.,  2007  
 
Plasma One-step  Same as above  
Same as above 
GAPDH, DEFA1, 
TRBV19, MYL4 
Maron et. al., 2007 
 
Plasma  Two step Qiagen Inc. 
Omniscript RT 
Reagent kit 
Qiagen Inc. 
QuantiTect Probe PCR kit 
hPL:  5’-CATGACTCCCAGACCTCCTTC-3’ (forward) 
  5’-TGCGGAGCAGCTCTAGATTG-3’ (reverse) 
  5’-(FAM)TTCTGTTGCGTTTCCTCCATGTTGG- 
  (TAMRA)-3’ (probe) 
ßhCG:  5’-CTACTGCCCCACCATGACCC-3’ (forward) 
 5’-TGGACTCGAAGCGCACATC-3’ (reverse) 
 5’-(FAM)CCTGCCTCAGGTGGTGTGCAACTAC- 
hPL, ßhCG Okasaki et al., 2006 
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1 FAM: 6-carboxyflourescein  
2 TAMRA: 6-carboxy-N,N, N’,N’-tetramethylrhodamine 
 (TAMRA)-3’ (probe) 
 
Whole blood  
 
Two step Qiagen Inc. 
Omniscript RT 
Reagent kit 
Qiagen Inc. 
QuantiTect Probe PCR kit  
 
Same as above 
 
hPL, ßhCG Okasaki et al., 2006 
 
Plasma  One-step  Applied biosystems: 
EZ rTth RNA PCR kit 
CRH: 5’-GCCTCCCATCTCCCTGGAT-3’ (forward) 
 5’-TGTGAGCTTGCTGTGCTAACTG-3’ (reverse) 
 5’(FAM)TCCTCCGGGAAGTCTTGG- 
 AAATGGC(TAMRA)-3’ (probe) 
CRH Ng et al., 2003b  
 
Plasma One-step  Applied biosystems: 
EZ rTth RNA PCR kit 
GAPDH:  
 5’-GAAGGTGAAGGTCGGAGT-3’ (forward) 
 5’-GAAGATGGTGATGGGATTTC-3’ (reverse)  
 5’-(6-FAM)-CAAGCTTCCCGTTCTCAGCC- 
 (TAMRA)-3’ (probe) 
hPL:  5’-CATGACTCCCAGACCTCCTTC-3’ (forward) 
  5’-TGCGGAGCAGCTCTAGATTG-3’ (reverse) 
  5’-(FAM1)TTCTGTTGCGTTTCCTCCATGTTGG- 
  (TAMRA2)-3’ (probe) 
ßhCG:  5’-CTACTGCCCCACCATGACCC-3’ (forward) 
 5’-TGGACTCGAAGCGCACAT-3’ (reverse) 
 5’-(FAM)CCTGCCTCAGGTGGTGTGCAACTAC- 
 (TAMRA)-3’ (probe) 
CRH: 5’-GCCTCCCATCTCCCTGGAT-3’ (forward) 
 5’-TGTGAGCTTGCTGTGCTAACTG-3’ (reverse) 
 5’(FAM)TCCTCCGGGAAGTCTTGG- 
 AAATGGC(TAMRA)-3’ (probe) 
 
GAPDH (reference), 
hPL, βhCG, CRH 
Tsui et al., 2004  
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1.4 Free mRNA markers in maternal blood 
1.4.1 Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
GAPDH is an enzyme which primary function assists the break down of glucose to energy and carbon 
molecules using its catalytic features (Nelson and Cox, 2005). It catalyzes the sixth step of the 
glycolysis, where Glyceraldehyde-3-phosphate (GAPD ) is converted into 1,3-Bisphosphoglycerate that 
is further used in the glycolysis. Below in Figure 1.4.1.1 the full reaction is depicted.   
 
Figure 1.4.1.1: The picture shows the catalytic function of GAPDH in the sixth step of the glycolysis (Nelson and 
Cox, 2005 ).  
The glycolytic process occurs in most eukaryotic cells and therefore GAPDH mRNA is a housekeeping 
gene, which makes it suitable as a reference gene in our study. 
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1.4.2 Beta-Human Chorionic Gonadotropin  (beta-hCG) 
The glycoprotein hormone, human Chorionic Gonadotropin (hCG) consists of two subunits referred to 
as α-human Chorionic Gonadotropin (α-hCG) and β-human Chorionic Gonadotropin (β-hCG). The 
latter will be the main focus of this section, though the function of hCG and the α-subunit of hCG will 
also be briefly introduced 
The primary function, known so far, of hCG is its involvement in maintenance of the corpus luteum 
during early gestation by maintaining the progesterone production (Cunningham, 2005). It mediates 
its actions through the LH-hCG receptor, which is expressed in various tissues. The receptor is 
predominantly expressed in the placenta but other tissues have also been reported to express it, 
including several fetal tissues and the maternal thyroid gland (Tomer et al., 1992).The cellular origin 
of hCG varies depending on the time of gestation. Human CG expression is observed in both 
cytotrophoblasts and syntiotrophoblasts less than 5 weeks along the gestation (Marou et al., 1992). 
Later in the pregnancy it is almost solely expressed by the syntiotrophoblasts (Cunningham, 2005). It 
is expressed highly in pregnant women but is also expressed in low concentrations in men and non-
pregnant women (Cunningham, 2005).  
Besides maintaining the corpus luteus, hCG has been associated with early stimulus of fetal testicular 
testosterone in male fetuses as a part of the sexual differentiation, acting as a surrogate for LH 
(leuteinizing hormone) (Cunningham, 2005) and might participate in angiogenesis, growth and 
implantation of the placenta (Filicori et al., 2005). Furthermore it has also been reported as being 
elevated in serum of nullipara women with pre-eclampsia or/and IUGR (Merviel et al., 2001) and may 
promote uterine vascular vasodilation and myometrical smooth muscle relaxation (Reviewed by 
Kurtzman et al., 2001). These findings make it partly interesting as a marker in the maternal blood 
when screening for IUGR and pre-eclampsia. At present hCG is used clinically to determine pregnancy 
because of the elevated concentration of hCG in the blood and urine of pregnant women when 
compared to non-pregnant women (Reviewed by Stenman et al., 2006).  
In general hCG has similar biological functions to that of the luteinizing hormone (LH). This is not 
surprising, as they both are members of the same glycoprotein hormone family, together with the 
follicle stimulating hormone (FSH) and thyroid stimulating hormone (TSH). The hormones in this 
family is heterodimers each consisting of an α- and a β-subunit, where all of the hormones have the α-
subunit in common but feature different β-subunits, which provide the hormone its specificities 
(Reviewed by Alevizaki and Huhtaniemi, 2002). Even though the β-subunit is different from one 
another depending on the hormone, the β-subunit of hCG and the β-subunit of LH is 80% identical, 
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which probably is why their biological functions are closely related (Reviewed by Stenman et al., 
2006). 
  
It should be noted that hCG and the other hormones are only biological functional if they contain the 
two subunits β and α. Separately the β-hCG and α-hCG might have their own functions independent 
from the united hCG hormone. However, not all agrees with this hypothesis. Alevizaki and Huhtaniemi 
(2002) states in their review that the two subunits have no individual biological activity and therefore 
the subunits only function together as the hCG hormone. Yet there are indications supporting the 
hypothesis of individual activity. Alpha-hCG has been shown to stimulate prolactin production in 
decidual cells3. Several studies shows that the β-hCG exerts growth-promoting activity, however it has 
no hCG function. Thus β-hCG has been spotted in several kinds of malignant tumours such as 
throphoblastic neoplasm4 (Cunningham, 2005). Therefore, it is currently under intense study as a 
potential tumour marker in different types of cancers, even cancers that does not originate in the 
trophoblast tissue, for instance biliary cancer and pancreatic cancer (Reviewed by Stenman et al., 
2006; Alfthan et al., 1992). 
Six genes clustered on chromosome 19 encode β-hCG and these are numbered β1, β2, β3, β6/ β7, β9/ 
β3, β5 and β8. β7 and β9 are alleles to β6 and β3, respectively, which is indicated by the slash. The β1 
and β2 genes are thought to be pseudo genes and are therefore never expressed, whereas the β6/β7 
genes are primarily expressed on benign non-trophoblastic tissue. The remaining genes, β3/β9, β5 
and β8, are expressed by trophoblastic and malignant tissues (Bellet et al., 1997). It is still not known 
why there are six genes that encode the β-subunit of hCG, for which reason it still has to be further 
studied. The product of the β-hCG-genes is a 145 amino acid long β-hCG protein (Reviewed by 
Alevizaki and Huhtaniemi, 2002). 
 
Considering, that the α-subunit is common in all the hormones of the glycoprotein family, it is not 
interesting to study it in our case, as the β-subunit constitutes the specificity of the intact hCG. As 
noted earlier the hCG hormone has been spotted in pre-eclamptic cases and presumably has some 
involvement in the activity in the vascular tissue of placenta. This attracts attention to investigate 
whether or not the gene expression, mRNA, of the β-hCG in maternal blood is also elevated in pre-
eclamptic women and in other vascular diseases of the placenta. In fact, Bartha et al. has in 2003 
studied the maternal serum concentrations of the β-hCG in pregnant women with pre-eclampsia and 
                                                          
3
 Decidual cells lines the inner layer of the uterus wall. It envelopes the embryo and forms a part of the placenta. 
4
 Trophoblastic neoplasm is a cancer type which is gestational or non-gestational in origin.   
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concluded that the β-hCG concentration is elevated in the maternal serum, when the pregnant woman 
suffers from pre-eclampsia. They also found that there is no correlation between fetal growth 
restriction and β-hCG, as the concentration of β-hCG in maternal serum was normal in the pre-
eclamptic women (Bartha et al., 2003). This gives us another reason for investigating the mRNA of β-
hCG as a potential marker used in non-invasive prenatal diagnosis of pre-eclampsia. 
Yet there has been no studies measuring the β-hCG mRNA in maternal whole blood, - serum or - 
plasma of pre-eclamptic women. However, there have been several studies measuring the quantity of 
β-hCG mRNA either in maternal serum, - plasma or - whole blood in healthy pregnant women.  
Ng et al. (2003A) demonstrated that maternal plasma β-hCG mRNA levels peaks during the first 
trimester in pregnant women without complications and thereafter it decreases. In addition, they 
showed that the β-hCG mRNA molecules are relatively stable and thereby this transcript is practical as 
a molecular marker in clinical use, e.g. for pre-eclampsia (Ng et al., 2003A). Another group of 
researchers, Tsui et al. (2004), have also studied the quantity of β-hCG mRNA in the plasma of healthy 
pregnant women. They detected 4969 copies of β-hCG mRNA per millilitre in the first trimester and no 
copies of β-hCG mRNA in the third trimester (Tsui et al., 2004). The same indication has later been 
shown by Ge and colleagues in 2005 using real-time RT-PCR and microarray detection. They did an 
additionally interesting finding as well – the level β-hCG mRNA in plasma of pregnant women carrying 
female fetuses was significant higher than in pregnant women carrying male fetuses.  
Hitherto quantity of β-hCG mRNA in maternal plasma has been investigated, however, it is not until 
the resent years that the quantity of β-hCG mRNA in maternal whole blood has been studied. Some 
experiments comparing the maternal cellular β-hCG mRNA level with the concentration of β-hCG 
mRNA in maternal plasma has been done but the results are contradictory as described in section 2.3.  
 
Although no studies have been published so far dealing with the correlation of pre-eclampsia and 
levels of β-hCG mRNA in maternal whole blood, it could be very interesting to investigate. This is based 
on the knowledge of the β-hCG protein and the otherwise β-hCG mRNA quantified. It would be 
interesting to study the mRNA in maternal whole blood, as this is a very new approach and few studies 
have been made in this regard. Furthermore, Okazaki et al. (2006) showed that the concentration of 
the transcript in maternal whole blood is significantly increased compared to samples of maternal 
plasma. As stated earlier in this section, β-hCG is associated with pre-eclampsia and it is elevated in 
serum of pregnant women suffering from this disorder. When β-hCG is increased during pre-
eclampsia, the mRNA of β-hCG might also be elevated. If this is true β-hCG would make a good 
potential molecular marker in diagnosing pre-eclampsia before the symptoms are established. 
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However, it is not likely that it can be used as a marker in IUGR, as the concentration of the β-hCG 
mRNA seems to be within the normal range.       
1.4.3 Human Leukocyte Antigen  (HLA-G)  
Human Leukocyte Antigen (HLA-G) is the main HLA Class Ib gene that is expressed by fetal trophoblast 
cells (King et al., 1996). The best described HLA-G alleles are HLA class Ia and II genes, these are also 
known as the classical HLA genes. The non classical Ib genes are, for several reasons, interesting in 
regards to investigations into pregnancy complications, such as pre-eclampsia (Reviewed by Hviid, 
2006). 
Compared to the classical Ia and II genes, the class Ib genes are to be very monomorphic (Kovats et al., 
1990; Crisa et al., 1997; Lila et al., 2001 Ishitani et al., 2003; Rebmann et al., 2003). Whereas the class 
Ia and II are a group of genes with maybe the highest degree of polymorphism observed in the human 
genome. (Harrison et al., 1993; Hviid et al., 2003). The most discussed one is 14 bp HLA-G, the 
homozygote form of this polymorph is associated with pre-eclampsia. Moreover many studies have 
shown significant decreased levels of HLA-G in placenta and in the blood circulation of pregnant pre-
eclamptic women (Reviewed by Hviid, 2006; Fujii et al., 1994; Hiby et al., 1999; Hviid et al., 2003).  It 
has also been suggested that HLA-G has other roles in the maintenance of pregnancy, including the 
participation in vascular remodelling by inhibiting the angiogenesis (Fons et al., 2006; LeBouteiller et 
al., 2007). 
Invasive trophoblast cells are the only cells known to express all three non-classical Ib genes. This had 
lead to the development of theories as to how these genes function in relation to each other in regards 
to implantation, as well as their influence on which immunological responses occur during pregnancy. 
HLA-G has been detected in cytotrophoblast cells from very early in the first trimester, and might 
already be expressed by these cells as early as in the blastocyst stage (Braude et al., 1988; Zeng and 
Schultz, 2005). Expression of this gene continues throughout the entire period of gestation. HLA-G 
mRNA can be found in many types of tissue, and not just placental tissue. The actual protein is 
restricted to a substantial expression on the membrane of the intravillious trophoblast cells, which is 
most definitely a part of the process in the maternal accept of the placenta. It has been suggested that 
this accept is due to immunological signals generated by the cytokines that are excreted as a reaction 
to the HLA class Ib antigens (Kovats et al., 1990; Le Bouteiller and Blaschitz, 1999; Morales et al., 
2003).  
The three non-classical Ib genes are all found expressed on the membrane of invasive trophoblast 
cells. This discovery theoretically points towards existing of a functional co-operation between these 
genes. The malfunction of one of these genes might trigger an up-regulation of another, thereby having 
a compensational affect. Another theory is that there might exist a synergy effect between these genes 
Fetal mRNA in maternal whole blood                        6/5/2008 
 
 36 
that in positive cases gives a correct and regulated immune response in regards to implantation of the 
semi-allogenic fetus (Reviewed by Hviid, 2006). HLA-G has an effect on the release of certain cytokines 
which are necessary in creating a healthy immune response under gestation. HLA-G has for example 
been shown to influence the stimulation of IL-10 receptors (Moreau et al., 1999) which initiate 
secretion of important anti-inflammatory cytokines involved in a Th2 immune response during 
pregnancy (Huizinga et al., 1999). A Th2 immune response is related to that of a healthy pregnancy 
without complications (Chaouat et al., 2004).  
Stimulating a healthy immune response in the mother, along with the monomorphic and restrictive 
characteristics of this antigen, makes HLA-G an interesting candidate for future studies of pre-
eclampsia.  
 
1.4.4 Corticotropin Releasing Hormone (CRH)  
Cortico Releasing Hormone (CRH) is a neurohormone, produced in hypothalamus, playing a central 
regulatory role in response to stress. To trigger its biological effect it binds to the two G-protein-
coupled membrane receptors CRH-R1 and CRH-R2, wherefrom its signals are transducted through 
several intracellular pathways (Wang et al. 2007).  
Apart from being released from the hypothalamus CRH has also been found to be expressed in the 
placenta, fetal membranes, trophoblasts and the syncytiotrophoblasts (Wang et al., 2007; Warren et 
al., 1994; Makrigiannakis et al., 2003), but still its biological functions regarding the human pregnancy 
remains to be fully understood (Wang et al., 2007; Ng et al.; 2003B). 
It has been shown that CRH has an immune/inflammatory function and that vast increment of CRH 
takes place locally in sites of inflammation. (Wang et al., 2007) 
Furthermore CRH has been associated with pathological mechanisms causing e.g. pre-eclampsia. 
(Wang et al., 2007) 
CRH is detectable in the maternal plasma after 18 weeks of gestation. (Warren et al., 1994)  
Levels of the placental CRH in the maternal circulation during pregnancy are significantly increased 
and elevates significantly during the last 6 weeks of the pregnancy (Frim et al., 1988; Warren et al., 
1994; Wang et al., 2007).  
The fact that CRH is increased during pregnancy might indicate that it participates in the regulation of 
placental immune responses. (Wang et al., 2007)  
As well as the level of CRH increases during the pregnancy in the placenta, a raise in CRH mRNA levels 
is observed (Frim et al., 1988). 
Furthermore an abnormal CRH-level is observed in pre-eclamptic women (Ahmed et al., 1995; Goland 
et al., 2000). The level in pre-eclamptic women was found to be as high as ten times higher than in 
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controls (Ng et al., 2003B) This fact has started speculations on whether or not CRH could be a 
possible biomarker applied in the diagnostics of pre-eclampsia. (Ng et al., 2003B, Purwosunu et al., 
2007)  
As mentioned above CRH is a hypothalamic hormone, which means it usually will not be present in the 
maternal plasma, at least not in amounts as large as seen in pregnant and pre-eclamptic women. 
Therefore it is concluded that CRH mRNA present in the maternal plasma must origin from the 
placenta. (Ng et al., 2003B). Another fact that supports this is that measurements done by Ng et al. and 
Purwosunu et al. before and after delivery showed that the maternal plasma-level of CHR mRNA drops 
radically within a few hours after birth. 
Conclusively it can be said that as CRH is observed in these extreme levels in the plasma of pre-
eclamptic women and that the levels are placenta-dependent makes it an interesting transcript for 
possible use in the diagnosis of pre-eclampsia. But as a last comment it has to be considered that, as 
CRH is not measurable in the early pregnancy, and thereby not relevant in pre-symptomatic diagnosis; 
it might not be as interesting as other transcripts measurable earlier in the pregnancy.  
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1.4.5 Alternative candidate genes: Limitations & Advantages 
1.4.5.1 Cytokines 
Due to insufficient trophoblast invasion, local hypoxia emerges in pre-eclampsia. This leads to 
stimulation of placenta to release placental factors into the maternal blood circulation, resulting in 
irregularities of the endothelial function. The factors released due to local hypoxia include cytokines 
(Tjoa et al., 2004). Studies show that the levels of interleukin-6 (IL-6) and tumour necrosis factor alpha 
(TNF-alpha), in the third trimester are almost at threefold level in pre-eclamptic women compared to 
non-pre-eclamptic women in their third trimester (Conard et al., 1998). Though, it is problematic that 
it is measured as increased during the third trimester as the symptoms of IUGR and pre-eclampsia 
would be established by then.  
 In Conard et al.’s study, no changes of the levels of other cytokines such as TNF-beta, IL-1-alpha and 
IL-10 were registered and therefore these might not be interesting as potential markers in the 
pregnancy related disorders. In another study by Serin et al., the usefulness of the TNF-alpha in the 
first and second trimester was questioned (Tjoa et al., 2004).  
The concentration of cytokinic receptor interleukin 2 (IL-2) [var koncentrationen højere eller lavere?] 
in the first trimester in women that later were diagnosed with severe pre-eclampsia (Eneroth et al., 
1998). Although IL-2 receptor could be detected as early as the ninth week of pregnancy, its detection 
unfortunately overlaps considerably with IL-2 receptor levels in the non pre-eclamptic control group. 
Other than IL-2, the usefulness of cytokines in the first and second trimester of pregnancy due to 
unaltered levels is questionable (Eneroth et al., 1998; Djurovic et al., 2002).  
 
1.4.5.2 Growth Factors  
Growth factors are of key importance during fetal growth and placentation (Tjoa et al., 2004). Vascular 
transformation and angiogenesis are essential processes for normal placental development (Ahmed et 
al., 2004). Irregular development of fetal vessels within the placental villi has been linked to IUGR and 
pre-eclampsia. Moreover, an appropriate trophoblast invasion is also dependent on endogenous 
activity. Vascular endothelial growth factor (VEGF), placenta growth factor (PlGF) and basic fibroblast 
growth factor (bFGF) have specific functions in a successful trophoblast invasion and therefore these 
could be expected to be good molecular marker in diagnosing pre-eclampsia or IUGR. Increased levels 
of bFGF is associated with pregnancy caused hypertension (Kurz et al., 2001) and mild pre-eclampsia 
(Hohlagschwandtner et al., 2002). Elevated level of bFGF is though not a good prognostic marker, 
because it cannot distinguish between severe and mild pre-eclamptic conditions (Hohlagschwandtner 
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et al., 2002). Other studies have shown different serum levels of angiogenic factors VEGF and PlGF in 
pre-eclamptic women (Reuvekamp et al., 1999; Torry et al., 1998; Baker et al., 1995; Sharkey et al., 
1996). Decreased serum levels of VEGF and PlGF (Reuvekamp et al., 1999; Torry et al., 1998) were 
seen in pre-eclamptic women, whereas Baker et al. (1995) and Sharkey et al. (1996) showed elevated 
levels of VEGF and PlGF. Furthermore Bosio et al. (2001) showed increased levels before the beginning 
of the disease. It is noted that in many VEGF related studies have had difficulties measuring VEGF 
levels due to its limited amount in serum. Decreased mid-trimester levels of P1GF have also been seen 
in women whom gave birth to growth restricted newborns (Tjoa et al., 2001). However, other studies 
have shown contradictory results. Unaffected PlGF levels were detected during gestation period (Ong 
et al., 2001) and at 15 weeks (Livingston et al., 2001). Usage of different time intervals in the studies is 
probably the cause of the inconclusive obtained results (Tjoa et al., 2004). Moreover, the likelihood of 
existence of different isoforms of PlGF should be considered and corrected for the particular assays 
(van Wijk et al., 2002).   
Since the PlGF-1 isoform is expressed in extravillous trophoblast cells, it is obvious to think that the 
isoforms is an important factor for trophoblast invasion and its expression is disturbed in women with 
pregnancy complications (Tjoa et al., 2004). Hepatocyte growth factor (HGF) is another growth factor 
that has increased levels at 14-21 weeks of gestation in women that give birth to growth restricted 
infants (Tjoa et al., 2003). On the other hand, HGF levels were measured as normal in women destined 
to become pre-eclamptic (Tjoa et al., 2004).   
 
1.4.5.3 Cellular Adhesion Molecules  
Adhesion molecules are open up for cells can stick together. Adhesion molecule expression is ectopic 
during abnormal placenta formation. Intracellular adhesion molecule 1 (ICAM-1) and vascular 
adhesion molecule 1 (VCAM-1) are both expressed by the endothelium in deciduous membrane, and 
are increased during pre-eclampsia. Since VCAM-1 and ICAM-1 are associated with placentation, 
increased levels may indicate disturbed placenta formation (Review by Tjoa et al., 2004). Levels of 
VCAM-1 are in steady raise in evident pre-eclampsia (Lyall et al., 1994; Djurovic et al., 1997; Phocas et 
al., 2000), and substantial higher levels of VCAM-1 in pre-eclamptic group of patients with IUGR, in 
comparison with patients suffering only of pre-eclampsia (Djurovic et al., 1997; Phocas et al., 2000). 
However, another study has found no change in VCAM-1 levels in the second trimester of pregnancy 
(Phocas et al., 2000). Many conflicting results have been reported regarding ICAM-1. Some studies 
show decreased levels of ICAM-1 (Phocas et al.,2000) or unaltered during pre-eclampsia (Hietala et al., 
2000; De Groot et al., 2000). Abnormal cell adhesion molecule is only instructive for the malfunction of 
endothelial cells. It is assumed that endothelial cells have no initial, but subordinated involvement in 
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the pathogenesis of pre-eclampsia only (Review by Tjoa et al., 2004). Endothelial activation was not 
detected at 18 weeks of gestation in women who later developed pre-eclampsia (Clausen et al., 2000). 
It is suggested that increased ICAM-1 and decreased VCAM-1 levels at 18 weeks of gestation show 
change in fetal trophoblast expression of adhesion molecules rather than reflection of maternal 
endothelial activation (Clausen et al., 2000).  
 Plasma selectin is also associated with pre-eclampsia (Bosio et al., 2001). Elevated levels of P-selectin 
and L-selectin are found in pre-eclampsia and coronary heart diseases. As a consequence of the 
indefinite and contradictory data, it is obvious that only markers which directly indicate abnormal 
changes in trophoblast cells early, should be focused on for the purpose of early diagnostic of pre-
eclampsia (Review by Tjoa et al., 2004).  
 
1.4.5.4 Fibronectin 
Fibronectins are glycoprotein’s which are placed on body fluid cell membranes. These Fibronectins 
have a tissue repairing function and are only produced when cells are damaged. Therefore fibronectins 
are seen as good potential good markers for prediction of endothelial cell damage (Review by Tjoa et 
al., 2004). Prior to onset of pre-eclampsia elevated levels of total fibronectin (e.g. fibronectin in all 
body fluids, not to be confused with cellular fibronectin) ( Yasumitzu et al., 1996; Gredmark et al., 
1999) and cellular fibronectin ( Taylor et al., 1991; Chavarria et al., 2002; Lockwood et al., 1990) are 
seen in pregnant women that develop pre-eclampsia later. Gredmark et al. (1999) found though no 
direct evidence for usefulness of total fibronectin. Paalberg et al. (1998) concluded that fibronectin is 
only a good marker for women destined to develop severe pre-eclampsia. In a similar study by Tjoa et 
al. (2004) the results for the low risk population with focus on first trimester were examined. The 
study indicated no change in fibronectin levels in pre-eclamptic women compared with the control 
group. In another study by Islami et el. (2001) with focus on a high risk population, underlined raised 
levels of fibronectin in pre-eclamptic women in their third trimester. Based on the inconclusive and 
unsettled results, which shows that fibronectin is only detectable at high levels and only when the 
disease has emerged. It can be concluded that fibronectin cannot be used as a good marker for pre-
symptom period (Tjoa et al., 2004).   
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1.4.5.5 Leptin 
The peptide hormone leptin is secreted by adipose cells and plays key role in body weight regulation 
and the efficiency of metabolic activity (Review by Tjoa et al., 2004). Mise et al. (1998) showed in a 
study elevated leptin values in pre-eclampsia. Leptin values were found to be almost four-fold in the 
end of pregnancy in the examined group compared with the levels they initially had shown (Vitoratos 
et al., 2001). Because leptin levels are significant higher in pre-eclamptic women, leptin is believed to 
play a role in pre-eclampsia pathogenesis (Review by Tjoa et al., 2004). In two independent studies 
leptin elevated leptin values were measured prior to the disease was evident (Anim-Nyame et al., 
2000; Chappel et al., 2002). Recently some studies have shown contradictory results. Chan et al. 
(2003) found no marked altered value of leptin before pre-eclampsia was clinically evident. 
Furthermore, no changes in the levels of plasma leptin were found in mild pre-eclamptic women 
compared with severe pre-eclamptics (Martinez et al., 2000). In addition two other studies showed 
decreased levels of leptin in pre-eclamptic women (Clausen et al., 2002; Laml et al., 2001). It is though 
more likely that levels of leptin are raised in the late second trimester (Anim-Nyame et al., 2000; 
Teppa et al., 2000; McCarthy et al., 1999). Leptin is therefore of no significant if the purpose is 
designing a non-invasive, preventive method for treatment of pre-eclampsia.  
 
1.4.5.6 C - Reactive Protein 
C – Reactive protein CRP is produced by the liver and it is associated with inflammations. CPR values 
are elevated in pre-eclampsia (Teran et al., 2001). Two-fold values of CRP were found in women who 
later developed pre-eclampsia (Wald et al., 2001).  It is unknown what the levels of CRP are prior to 
pregnancy, they have not been measured, moreover, elevated CRP are also elevated in obesity patients 
Visser et al. (1999) and patients with coronary heart diseases (Rifai et al., 2002). It is therefore 
importent to consider the poosibility that levels may be high in advance in some women due to other 
factors (Review by Tjoa et al., 2004). Again there are contradictory results. Diurovic et al. (2002) and 
Savvidou et al. (2002) showed no marked raised levels of CRP in women who later developed pre-
eclampsia or IUGR.  
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1.4.5.7 Neuropeptides 
As mentioned in section 2.2.1 hypertension is one of the main signs of pre-eclampsia. This fact has 
triggered attention to vasoconstrictors as possible markers for pre-eclampsia. Increased values of 
neurokinin B (NKB) is associated with pre-eclampsia, this is confirmed by Page et al. (2000). NKB is 
related to specific neuropeptides tachykinins (Review by Tjoa et al., 2004). Since pre-eclampsia is 
believed to be a consequence of poor placental perfusion, and tachykinins are believed to be placenta 
perfusion regulators, there might be a link between pre-eclampsia and tachykinins (Page et al., 2001). 
Page et al. (2001) suggest that elevated values of NKB-1 and-2 may be released to the system due to 
deficient trophoblast invasion. Page et al. (2001) also suggest that NKB may be involved with other 
pregnancy complications such as IUGR and miscarriage. The possibility of early NKB expression is 
indicative for IUGR and pre-eclampsia, has yet to be proven in future studies (Tjoa et al., 2004).  
 
Fetal mRNA in maternal whole blood                        6/5/2008 
 
 43 
2 Part II: Experiments and results 
2.1 Introduction to the experimental issue 
It has been known for some years that there are fetal free nucleic acids in maternal blood. Thus, there 
have been several experiments focusing on different molecular markers in maternal plasma or serum 
to find a new non-invasive prenatal method of diagnosing various pregnancies, both using DNA and 
mRNA gene sequences as potential markers. However, few have explored fetal mRNA in maternal 
whole blood (also referred to as the cellular component of the blood), though it has been indicated by 
Okazaki et al., 2006 that fetal mRNA sequences are increased in maternal cellular blood when 
compared to the same sequences in the maternal plasma. Therefore, we found it interesting to explore 
the possibilities of extracting fetal mRNA from maternal cellular blood and subsequently quantify it 
using Real-Time Reverse Transcription Polymerase Chain Reaction (rtRT-PCR). 
In the light of our interest above-mentioned, the aim with the experiments we performed was to prove 
that it is possible to extract total mRNA from the cellular component of blood. To do this we used 
different extracting and PCR kits to see which gave the best outcome. Furthermore, we tried to 
quantify specific fetal mRNA sequences in maternal whole blood to see if it could be used as a potential 
non-invasive prenatal method to diagnose pre-eclampsia and IUGR before their symptoms establish. 
Unfortunately, we did not during the few weeks experiments were conducted have access to pregnant 
women suffering from either one or both of the disorders and therefore, it has not been possible to 
make any experiments as regarding specific fetal mRNA levels in whole blood of women with pre-
eclampsia or IUGR or both.  
 
In the first experiment the purpose was to extract total RNA from whole blood and make GAPDH cDNA 
using the two-step rtRT-PCR kit, “TaqMan Gene Expression Cells-to-CT Kit” (from Applied 
Biosystems). In our second experiment we used another extraction kit, the “PureLink Total RNA Blood 
Purification Kit” (from Invitrogen) to extract total RNA and another rtRT-PCR kit, the “LightCycler480 
RNA Master Hydrolysis Probes” (from Roche) to make GAPDH cDNA. The purpose of this experiment 
was to explore if this one-step rtRT-PCR kit was better then the first two-step RT –PCR kit used. 
Furthermore, we wanted to see if the concentration of cDNA in the samples has an impact of the 
results. Additionally, we tested whether the choice of collecting the blood samples in EDTA tubes 
versus heparin tubes had an impact on the results. 
In the subsequent third experiment the aim with the experiment was to extract total RNA from whole 
blood once again. However, this time we wanted to quantify GAPDH, β-hCG, HLA-G and CRH. In the 
fourth and final experiment we wanted to use the same extraction method as in the last to 
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experiments, only this time we also wanted to see if the extraction of RNA and the final result, would 
improve if the red cell lysis was not preformed during the extraction of the RNA. 
 
The general materials and methods are outlined below followed by a presentation of our results, 
which will discharge into a discussion of the results. 
2.2 Materials and methods 
Subjects and blood sampling 
The state of the persons the blood samples were collected from and the amount of blood collected is 
described in the four tables below, correlating to each of the four experiments performed. In which 
tube the blood was collected in is also stated in the tables. However, in the first experiment there were 
taken two samples of each person, where one was used in the actual extraction of RNA and the other 
were used to calculate the total amount of leukocytes.  
Ex.1 
Blood 
sample 
EDTA-/heparin 
tube 
Blood volume RNA is extracted from 
(µl) 
Pregnant/ Non pregnant/ 
Male 
1 EDTA 250 Non pregnant female+ male 
2 EDTA 250 Non pregnant female + male 
3 EDTA 250 Non pregnant female + male 
4 EDTA 500 Non pregnant female + male 
5 EDTA 500 Non pregnant female + male 
6 EDTA 500 Non pregnant female + male 
 
Ex.2 
Blood  
sample 
EDTA-/heparin 
tube 
Blood volume RNA is extracted from 
(µl) 
Pregnant/ Non pregnant / 
Male 
(A) EDTA 250 Non pregnant 
(B) EDTA 500 Non pregnant 
(C) Heparin 250 Non pregnant 
(D) Heparin 500 Non pregnant 
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Ex.3 
Blood 
sample 
EDTA-/heparin 
tube 
Blood volume RNA is extracted from 
(µl) 
Pregnant/ Non pregnant/ 
Male 
1 EDTA 250 Pregnant 1(12 weeks) 
2 EDTA 250 Pregnant 2 (11 weeks) 
3 EDTA 250 Pregnant 3 (19 weeks) 
4 EDTA 500 Pregnant 1 (12 weeks) 
5 EDTA 500 Pregnant 2 (11 weeks) 
6 EDTA 500 Pregnant 3 (19 weeks) 
 
Ex.4 
Blood  
sample 
EDTA-/heparin 
tube 
Blood volume RNA is extracted from 
(µl) 
Pregnant/ Non pregnant/ 
Male 
G1 EDTA 500 Pregnant 1 (20 weeks) 
G2 EDTA 500 Pregnant 2 (18 weeks) 
IG1 EDTA 500 Non pregnant 1 
IG2 EDTA 500 Non pregnant 2 
G1 PBS* EDTA 500 Pregnant 1 (20 weeks) 
G2 PBS* EDTA 500 Pregnant 2 (18 weeks) 
IG1 PBS* EDTA 500 Non pregnant 1 
MF EDTA 500 Male 
*In the samples marked “PBS”, there has not been preformed red cell lysis during the extraction of 
RNA. 
 
Processing of blood samples and RNA extraction 
In the first experiment the leukocytes of the two blood samples were counted as there is a maximum of 
100.000 cells from where the RNA can be extracted. Thereafter, a blood volume corresponding to 
100.000 leucocytes were taken from the second blood tube to a DNAse/RNAse-free Eppendorf tube. 
Lysis Buffer (L5 from the “PureLink Total RNA Blood Purification Kit” catno K1560-01 Invitrogen) was 
added to lyse the erythrocytes. The Eppendorf tube was centrifuged at 4˚C at 400x for 10 minuttes. 
The supernatant was discarded as the pellet contained the leucocytes. 
The remaining RNA extraction was performed using “TaqMan Gene Expression Cells-To-CT” kit 
(Applied Biosystems/ catno AM1728). The process was performed according to the instructions of the 
manufacture and the samples were applied in a LightCycler480 real time PCR instrument.   
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The RNA extractions in the remaining experiments were performed using only the “PureLink Total 
RNA Blood Purification Kit” (Invitrogen/ catno K1560-01) and also following this manufacturer’s 
instruction. 
A more elaborate description of the materials and methods used is presented in Appendix. 
  
Real-time reverse transcription PCR (rtRT-PCR)  
As the “TaqMan Gene Expression Cells-To-CT” (Applied Biosystems/ catno AM1728) is a two-step 
rtRT-PCR kit, the reverse transcription in the first experiment was a part of the kit and therefore, also 
performed according to the protocols of the manufacturer, using our own GAPDH primers and TaqMan 
probe, though (see Appendix to get more elaborate describtion). Two rtRT-PCR mixes were made and 
the aliquot RT-reaction (cDNA sample) was added so that the two mixes had various concentrations of 
cDNA. 
In the remaining experiments the one-step RT-PCR kit, “LightCycler480 RNA Master Hydrolysis 
Probes” (Roche/ catno 04991885001), was used. The RT-PCR mixes were made according to the 
manufacturer’s instructions, using different primers and probes corresponding to the mRNA 
transcript we wished to quantify. Thereafter, mixes were distributed into individual PCR wells and the 
adequate RNA extraction was added. One of the samples in each RT-PCR mix was made as a negative 
control to confirm that the kit was not contaminated.   
In the second experiment five PureLink mixes were made. The first three mixes were distributed into 
the individual PCR wells with various concentrations of RNA extraction. The fourth mix contained no 
enzyme that were capable of making cDNA, hence if any signal was to show in this sample, it would 
show amplification of genomic GAPDH DNA and not of GAPDH cDNA. The last sample was a modified 
mix of the PureLink kit, so we could test the cDNA made from the Cells-To-CT experiment.  
In addition to running rtRT-PCR of the GAPDH, β-hCG, HLA-G, and CRH samples in the third 
experiment, a control of genomic DNA was made for the β-hCG sample, where the RT-PCR mix did not 
contain an enzyme capable of making cDNA. Such a control sample was also made for CRH and GAPDH 
in the fourth experiment in addition to running the rtRT-PCR of the GAPDH, β-hCG, and CRH samples.          
 
The primers and probes used in the rtRT-PCR are described in Appendix. Furthermore, a detailed 
description of the features of rtRT-PCR and the use of Taqman probes is also specified in Appendix. 
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2.3 Results 
In the first experiment we performed, using the “Taqman Gene Expression Cells-to-CT Kit”, there was 
no clear rtPCR-signal visible in the samples. Hereby, we could conclude that this extraction and two-
step rtRT-PCR kit did not work in our case. It could be due to our choice of rtRT-PCR instrument as this 
is not manufactured by the Applied Biosystems that fabricate the kit used. However, it could also be 
because the kit simply is not produced to this kind of cell type. In the instruction manual of the kit it 
says that it can be applied in any analysis of mRNA from cultured cells, which the cells, in our case, 
were not. 
 
The lack of result in the first experiment led us to try out a new rtRT-PCR kit, the “LightCycler480 RNA 
Master Hydrolysis Probes” manufactured from Roche. Thus we this time used a kit that was 
manufactured by the same fabricant as the real time PCR instrument, we had access to. We also 
changed the RNA extraction kit so the input-volume of whole blood was larger (500µl). Hereby more 
mRNA could be extracted and it was furthermore even more pure. The changes in the extraction- and 
rtRT-PCR method resulted in a flourecence signal derived from amplified GAPDH cDNA. The result is 
depicted below in figure 2.3.1.   
   
 
Figure 2.3.1: The curves show the amplification of GAPDH cDNA in various concentrations using the PureLink 
extraction kit and testing of the cDNA made in the first experiment with the Cells-to-CT Kit. The red lines indicate 
the cDNA samples and the green lines indicate the negative controls (water instead of RNA in the rtRT-PCR mix) 
performed at each rtRT-PCR mixture made. The blue circle shows the area of the E samples (the samples from 
the two-step RT-PCR experiment, Cells-To-CT) and the red circle indicate the D samples (the samples with no 
enzyme to make cDNA). 
 
B(B) 
C(B) 
E samples D samples 
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As expected and as it should be, the negative controls of the samples (indicated by the green linies) 
show no amplification of cDNA. As seen in the previous experiment, the samples treated with a two-
step RT-PCR kit gives a poor result (blue circle at figure 2.3.1) compared to those with the one-step 
RT-PCR kit (the red curves at figure 2.3.1).  The samples containing enzymes that cannot make cDNA 
(the red circle indicated on figure 2.3.1) shows a very weak signal during the last 10 cycles of the 
sample. Thus, it is possible to amplify a little PCR product despite that the forward primer is spanning 
across an intron or a small level of mispriming is occuring. This is disturbing as in theory it should not 
be possible, especially as the intron is more than 1000 bp long.      
 
Various concentrations of GAPDH cDNA 
PCR mixture 
(RNA sample) 
Cp PCR mixture 
(RNA sample) 
Cp PCR mixture 
(RNA sample) 
Cp PCR mixture 
(RNA sample) 
Cp 
A (I) 19,9
4 
B (A) 19,5
1 
C (A) 20,5
7 
D (A) 35,6
5 
A (II) 20,2
5 
B (B) 19,3
0 
C (B) 19,5
3 
D (B) 33,9
9 
A (III)  B (C)  C (C) 23,1
8 
D (C) 39,4
3 
A (IV) 20,9 B (D) 21,1
8 
C (D) 21,1
5 
D (D) 37,7
5 
A (Water)  B (Water)  C (Water)  D(Water)  
Table 2.3.1: The table shows the Crossing point (Cp) and the cDNA samples in the experiment with the GAPDH 
cDNA in various concentrations. A, B, and B indicates the real time RT-PCR mixes, where A is least diluted and C 
is the most diluted. D is a control of the kit and contains no enzymes that are capable of making cDNA. The 
different preparations of the RNA samples (I), (II), (IV) and (VI) is specified more elaborately in section 2.2 and 
Appendix 
 
If we compare the Cp values of the different samples A, B and C from table 2.3.1 it infers that the 
different concentration of cDNA in the samples does not have a significant importance regarding the 
results. For instance this is seen if we compare the Cp values of sample B(II) and sample C(II), which is 
nearly the same, even though  the concentration of RNA extract put into sample B is twice as much as 
in sample C. Whether the RNA is extracted from 250µl or 500µl does not seem to play a role either, 
which for instance is seen by comparing the Cp values of the (I) and (II) extraction samples. There 
seems to be a slight difference in regard to which anti coagulant tube the blood sample was collected 
in, where blood samples collected in EDTA tube gave the best results, given the lower Cp values, cf. 
sample (I) and (II) compared to (III) and (IV). 
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From the experiment outlined above we could conclude that it did not have a significant importance at 
which concentration total RNA was put into the samples and that the Purelink RNA extraction kit 
combined with the LightCycler480 rtRT-PCR kit gives a positive result of cDNA. In addition EDTA tube 
seems to be preferable both in the literature and our experiments confirmed that the usage of EDTA 
tubes to collection of blood samples gives a slightly better result.  
These observations we applied in another experiment trying to amplify GAPDH cDNA, β-hCG cDNA, 
HLA-G cDNA and CRH cDNA. 
Depicted below in figure 2.3.2 is the result of the amplification of GAPDH cDNA together with the 
standard concentrations of GAPDH, which is applied in calculating the concentration of our cDNA 
samples of GAPDH with an unknown concentration. The brown curves indicate the amplified standard 
samples. The green curves indicate the negative controls, where water has been applied instead of 
RNA to the samples. The red curves are the samples of GAPDH cDNA with unknown concentrations, 
which we wish to determine.   
 
 
Figure 2.3.2: The curves show the amplification of GAPDH cDNA. The brown curves indicate the standard 
samples of GAPDH cDNA with known concentrations; the green curves indicate the negative control and the red 
curves demonstrate our samples with GAPDH cDNA with an unknown concentration. 
 
The negative control in this sample shows no result (green lines), which verifies that the RT-PCR kit 
we use is not contaminated. Depicted below in Figure 2.3.3 is the standard curve calculated from the 
standard samples of GAPDH. The curve has been calculated by the computer program that 
accompanies the real time PCR instrument, LightCycler480 from Roche.  
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Figure 2.3.3: The standard curve 
calculated from the standard samples 
of GAPDH. 
 
 
 
 
 
 
The matching data of the standard curve is shown in Table 2.3.2 below. As we can see from the results 
the first two standard dilutions of GAPDH give no result. This indicates that there the concentrations of 
the standard copies are too low. 
 
 
Table 2.3.2: The table shows the various standard 
samples, their Cp values and the calculated 
concentration. The samples were made in duplicates 
and therefore there are two results in Cp value and 
two in concentration in every sample measured. 
 
 
 
The standard curve and the data from the standard samples are used in calculating the concentrations 
of our samples of GAPDH with an unknown concentration. This is also calculated by the 
LightCycler480 real time RT-PCR computer program and the results are depicted in Table 2.3.3. 
 
 
 
Table 2.3.3: The table reveals the 
concentrations and Cp values of our GAPDH 
samples with an otherwise unknown 
concentration. The samples were made in 
duplicates. Thus, there are two results of 
every sample. 
Values of GAPDH cDNA 
Sample Cp (duplicated) Concentration (duplicated) 
A 1 20,31 / 20,27 2,90x104/ 2,98x104 
A 2 20,51 / 20,13 2,52x104/ 3,27x104 
A 3 19,82 / 20 4,05x104 / 3,59x104 
A 4 20,75 / 20,84 2,14x104 / 2,01x104 
A 5 20,19 / 20,25 3,15x104 / 3,01x104 
A 6 21,8 / 21,99 1,04x104 / 9,15x103 
Values of GAPDH standard samples 
Sample Cp (duplicate) Concentration (duplicate) 
Standard 10
1 
- - 
Standard 10
2 
- - 
Standard 10
3 
26,1 / 25,55 8,79x102/1,14x103  
Standard 10
4 
22,01 / 21,65 9,02x103/ 1,15x104 
Standard 10
5 
18,73 / 18,3 8,56x104/ 1,15x105 
Standard 10
6 
15,19 / 15,21 9,66x105 / 9,54x105 
Standard 10
7 
11,79 / 11,69 9,95x106 / 1,07x107 
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From the results outlined in Table 2.3.3, we can conclude that we have been able to extract total RNA 
and quantify GAPDH-mRNA using one-step rtRT-PCR. 
We performed the same experiment with HLA-G. However we found that no cDNA could be detected. 
The graph of HLA-G cDNA amplification is shown in Figure 2.3.4. 
 
 
Figure 2.3.4: The figure shows the amplification curves of HLA-G standard samples with a known concentration 
(brown curves) and the HLA-G cDNA samples (green lines). 
 
On the basis of the amplification curves in Figure 2.3.4 we can conclude that it was not possible to 
amplify or detect any sample HLA-G cDNA] (green lines). It could be due to pipette mistake during the 
preparation of the rtRT-PCR mixes as some of the standard samples have not been amplified either. 
We have excluded the standard curve calculated and the matching data of the standard samples as 
these seemed irrelevant since no result was to be seen in the HLA-G cDNA samples. 
Unfortunately, we must also conclude from our experiment with β-hCG, which was performed in the 
same way that we could not amplify any β-hCG either. The results from this experiment are shown in 
Figure 2.3.5. 
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Figure 3.3.5: The figure depicts the amplification curves of the β-hCG standard samples (the brown curves) and 
the amplification curves of the β-hCG cDNA samples (indicated by the green lines). 
 
The green lines in the amplification curves of the β-hCG cDNA samples indicate that there is no 
detectable β-hCG cDNA in the samples. Again this can be a due to the extraction method. Indeed, we 
did also make a control for genomic β-hCG DNA but no genomic DNA was detected. These samples are 
among the β-hCG cDNA samples, also indicated in green lines. 
An interesting finding was observed when we applied the same methods and materials trying to 
amplify and quantify cDNA of CRH. As depicted in Figure 2.3.5, we got a clear amplification curve of the 
CRH samples. 
 
Figure 2.3.5: The figure shows the amplification curve of cDNA CRH samples. The red curves indicate the cDNA of 
CRH and the green line indicates a negative control, where water was used instead of total RNA in the samples. 
 
The red curves in Figure 2.3.5 indicate that there has been amplified CRH cDNA in the samples and the 
green line indicates that the rtRT-PCR mixes are not contaminated. However, the primers we used in 
this experiment were placed within the same exon, and therefore, the curves might show amplification 
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of genomic CRH DNA instead of CRH cDNA. To eliminate uncertainty of what we amplified, we made a 
control of genomic CRH DNA by having no enzyme to make cDNA. Additionally, we performed one 
more test of CRH cDNA. Thus we can compare the two sample types and if the Cp values of the two 
different samples are similar, we can conclude that the curve we saw in the previous experiment is an 
amplification curve of genomic CRH DNA. The result is shown in the Figure 2.3.6. 
 
Figure 2.3.6: The amplification curve show a control sample for genomic CRH DNA and samples of CRH cDNA. 
The red circle indicates the area where most of the control samples of genomic DNA are located. The blue circle 
indicates where most of the CRH cDNA samples are located. The remaining curves are mixed cDNA - and 
genomic DNA samples. 
 
As seen in Figure 2.3.6 the CRH genomic DNA samples and cDNA samples seems to have more or less 
the same Cp value. The various samples Cp values are stated below in Table 2.3.4.  
 
Cp values in CRH genomic DNA samples and CRH cDNA 
samples 
Sample Cp Sample           Cp 
G1 (cDNA) 25,53 G1 (genomic DNA) 27,5 
G2 (cDNA) 25,61 G2 (genomic DNA) 27,03 
IG1 (cDNA) 25,36 IG1 (genomic DNA) 26,75 
IG2 (cDNA) 26,42 IG2 (genomic DNA) 27,96 
G1 PBS (cDNA) - G1 PBS (genomic DNA) 34,35 
G2 PBS (cDNA) 31,21 G2 PBS (genomic DNA) 34,38 
IG1 PBS (cDNA) - IG1 PBS (genomic DNA) 35,19 
MF (cDNA) 23,21 MF (genomic DNA) 26,38 
Water (cDNA) - Water (genomic DNA) - 
Table 2.3.4:  The table show the Cp values of the genomic DNA samples and the cDNA samples. 
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Unfortunately, the Cp values of the genomic DNA samples and the Cp values of the cDNA sample are 
very similar. Thus, the amplification of CRH that we saw in the previous experiment must have been 
genomic DNA and not cDNA. This is most likely because the primers and probe matching the CRH 
sequences are located within the same exon, as mentioned before, and do not span over an intron. 
Therefore, if one should optimize this experiment of CRH quantification, the use of another set of 
primers separated by an intron, would be an optimal solution to this issue.  
It is very interesting, however, that Ng et al. (2003B) achieved good results when using the same set of 
primers as us. Maybe the fact that they extracted RNA from plasma instead of whole blood plays a role 
in the matter. As stated above enclosed genomic DNA in the RNA extraction is a problem in our study, 
even though a treatment with DNase I was performed but appently it was not effective enough. In the 
study by Ng et al. (2003B) controlles without reverse transcription enzymes was performed and were 
negative; hence, they most likely detected CRH mRNA/cDNA. 
 
It should be noted that in the new experiment with CRH cDNA and -DNA samples, some of the samples 
had a change in protocol from the previous experiment. Due to the lack of result regarding the various 
fetal gene sequences in the previous experiments, we changed the protocol in some of the samples. 
The change consisted in not carrying out the red blood cell lysis in some of the samples and see if this 
gave a better result as the results achieved by Ng et al. (2003A). Thus, the protocol change was 
inspired by the article of Ng et al. (2003A). The change in protocol as regarding the CRH sequence did 
not have any significant effect. 
Besides making a control for genomic CRH DNA, we also performed such a control to test in the 
amplification of GAPDH sequences. The results are shown in figure 2.3.7.  
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Figure 2.3.7: The amplification curve show amplification of GAPDH cDNA, standard samples of GAPDH and 
amplification of genomic GAPDH DNA. The brown curves indicate the amplification of the standard samples. The 
green lines indicate the negative controls of GAPDH (the samples contain water instead of RNA). And the red 
curves indicate the amplification of the GAPDH cDNA samples and genomic GAPDH DNA samples. The genomic 
GAPDH DNA samples are the red curves located within the blue circles. 
 
The rtRT-PCR mix we used is not contaminated, which is indicated by the green lines showing no 
amplification or signal. Some genomic GAPDH DNA has been amplified but the distance between the 
samples of GAPDH cDNA and GAPDH DNA (indicated by the blue circles in Figure 2.3.7) imply that it is 
cDNA we mostly have amplified in the previous experiments with GAPDH. We can also see this by 
comparing the Cp values of the GAPDH cDNA samples and the genomic GAPDH DNA samples, which is 
outlined in Table 2.3.5. 
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Concentrations and Cp values of GAPDH cDNA and genomic GAPDH DNA 
Sample           Cp Concentration Sample Cp 
G1 (cDNA) 13,44 9,83x106 G1 (genomic DNA) 28,88 
G2 (cDNA) 19,02 2.34x105 G2 (genomic DNA) 29,68 
IG1 (cDNA) 19,05 2,29x105 IG1 (genomic DNA) 28,49 
IG2 (cDNA) 19,32 1,92x105 IG2 (genomic DNA) 28,73 
G1 PBS (cDNA) 21,9 3,41x104 G1 PBS (genomic DNA) 38,08 
G2 PBS (cDNA) 23,94 8,71x103 G2 PBS (genomic DNA) 36,1 
IG1 PBS (cDNA) 23,2 1,43x104 IG1 PBS (genomic DNA) 37,29 
MF (cDNA) 17,96 7,76x105 MF (genomic DNA) 29,5 
Water (cDNA) - - Water (genomic DNA) - 
Table 2.3.5: The table shows the concentrations and Cp values of GAPDH cDNA samples and the Cp values of the 
genomic GAPDH DNA samples. To get a more elaborate description of the preparations of the different samples, 
see section 2.2  
 
If we compare the Cp values of the two different samples, we see that signal of GAPDH cDNA occurs 
many cycles before the genomic DNA does. If we further compare these values to the previous 
experiment done with the GAPDH mRNA sequence, we see that the Cp values are consistent between 
19 and 22 (See table 2.3.3). Thus, we must have detected GAPDH cDNA in the previous samples and in 
this cDNA sample. Below, the standard curve and matching data used to calculate the concentrations of 
the GAPDH cDNA is depicted, figure 2.3.8 and Table 2.3.6. 
 
 
figure 2.3.8: The figure shows the 
standard curve of the GAPDH  
standard samples. 
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Table 2.3.6 The table shows  
the concentration, Cp values and  
standard values of the GAPDH  
standard samples. 
 
As seen in the previous experiments, no PCR-signals were obtained with the two first standard 
dilutions (see figure 2.3.2 for comparison). This might be because the lowest concentrations of the 
standard inhibit the results. An interesting feature of these new data is that the third standard sample 
and the last standard sample also seem to give no applicable result. However, the duplicate samples 
correlating with the two standard samples give a result. Thus, an error must have been conducted in 
the pipette of the standards or in pipette of the rtRT-PCR mixes. 
Even though we changed the protocol for some of the samples in hope of detecting β-hCG cDNA, we 
failed to get any result. A little β-hCG cDNA might have been present in the samples, which simply 
could not be detected using the applied assay.  
The results of β-hCG cDNA are depicted in figure 2.3.9. 
 
Figure 2.3.9: The figure depicts the result of our β-hCG cDNA samples (indicated by the green lines) and the β-
hCG standard samples (indicated by the brown lines). 
 
We have chosen not to show the standard curve and the matching data since no result of our β-hCG 
cDNA samples was obtained. 
Cp value and concentration of GAPDH standard samples 
Sample Cp (duplicated) Concentration (dublicated)           
Standard 10
1 
- - 
Standard 10
2 
- - 
Standard 10
3 
-/ 28,03 -/ 1,00x10
3 
Standard 10
4 
23,68/ 23,51 1,03x10
4
 / 1,16x10
4 
Standard 10
5 
20,52/ 20,34 8,56x10
4
 / 9,68x10
4 
Standard 10
6 
16,9/ 17,01 9,17x10
5
 / 9,00x10
5 
Standard 10
7 
13,31/- 1,08x10
7
 / - 
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3  Discussion/conclusion 
3.1 Discussion of the results 
It should be noted that the following conclusions deduced from the results above in section 2.3 are 
based on very few samples and experiments; hence, a reservations should be taken in regards to all 
the conclusions. 
We were able to extract total RNA from whole blood and quantify the amount of GAPDH mRNA (cDNA) 
in different samples. The results also inferred that the concentration of cDNA do not have a significant 
impact on the final results of the rtRT-PCR-product. Furthermore, we also showed that the 
amplification we made of the samples was mainly cDNA but apparently also genomic DNA was present 
to a certain extent although we treated the samples with DNase.  
When the amplification of CRH samples was performed it was clear that the amplified DNA was 
genomic CRH DNA and not the CRH cDNA as expected. The cause of this could be the location of the 
used primers. These were located within the same exon and are therefore able to amplify genomic 
DNA to the same degree as cDNA. As stated in the results in section 2.3, the optimal solution to this 
issue is to choose two primers located in two different exons spanning over an intron and at least one 
of the primer sequences spanning an exon-exon junction. 
Considering a two-step rtRT-PCR or a one-step rtRT-PCR method it was clear in our case that the one-
step rtRT-PCR kit was the most optimal. Furthermore, this is also the simplest method and the most 
practical if applied in the clinic. 
However, it should be noted  
 
Unfortunately, we were not able to quantify any mRNA transcripts associated with the fetus or the 
placenta in whole blood of pregnant women or non-pregnant individuals.  
The lack of results could be due to many aspects in the procedures. The procedure in the “PureLink 
Total RNA Blood Purification Kit” (from Invitrogen)” might not be optimal for purifying feto-placental 
mRNAs or maybe there were insufficient trophoblast cells in the samples.  
The results indicated furthermore that collecting the blood samples in EDTA tubes results in a slightly 
better outcome compared to heparin tubes. However, maybe using the PaxGene RNA blood tubes 
(from PreAnalytix) to collect blood samples, would give a better result, as these tubes contain RNA 
stabilising reagents (see section 1.3.4). There might be other tubes, which also have RNA conservation 
features. Furthermore, the primers we used and the probes could also be the cause of our lack of 
results as polymorphisms, which has not been described before, is impossible to take into account. 
This would be highly unfortunate if this is the case. Considering, that the synthetic standard samples of 
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CRH, β-hCG and GAPDH showed positive results we can conclude that the PCR-process performed was 
effective. But of course a synthetic standard sample is somewhat different to original cDNA samples. 
We could however, also conclude that the PCR-process performed of CRH cDNA and GAPDH cDNA 
samples were effective as well.  
Considering, that the applied primers and probes complementary to the GAPDH gene sequence and 
CRH gene sequences showed positive results, we can conclude that having the rest of the primers and 
probes to the other gene sequences, not matching the gene sequences are highly unlikely. 
The collection of the blood samples from pregnant women was obtained from women early in 
pregnancy, where the highest expression of the genes we examined has been observed. Therefore the 
time of collecting of the blood samples seems not to be a significant source of error. For instance, β-
hCG has been observed to peak during the first trimester so this transcript ought to be detectable in 
the blood samples we obtained (Okazaki et al., 2006). However, this was not the case as mentioned 
earlier.  
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3.2 Discussion and future aspects 
Even though no feto-placental mRNA in maternal whole blood was detected in our study, it should be 
kept in mind that we only performed small pilot studies and therefore this does not necessarily 
indicate that it is impossible as a few published studies also claim (Maron et al., 2007), however, some 
controversy exits. In our pilot studies we could detect GAPDH cDNA using the applied methods. As 
mentioned in section 3.4 the results also indicated that the concentration of cDNA in the samples was 
not of significant importance. However, it should be noted that this only were indicated within the 
interval of concentrations that we examined. If the concentration of specific mRNA/cDNA, which only 
exist in certain cells, decrease to a certain level, the mRNA/cDNA cannot be detected. 
As mentioned earlier newer studies have indicated that feto-placental mRNA in the whole blood 
produce better rtRT-PCR-signals; hence a better sensitivity is seen. Through our pre-study we were 
not able to infer as to whether total RNA in whole blood compared to plasma has an increase of 
sensitivity; however the study by Okazaki et al. (2006) have indicated that this has to be reproduced in 
a range of independent studies.   
If mRNA markers in maternal whole blood should be investigated further in relation to diagnosis of 
pre-eclampsia and IUGR, however, the studies ought to be more streamlined by looking at the previous 
experiments performed and described in the literature. It does have an impact on the final results 
whether the maternal blood applied in the study is derived from a pregnant women in first, second or 
third trimester. The new method is of no use in a clinical aspect of diagnosing pre-eclampsia and IUGR 
if the specific mRNA biomarker is not detectable in early gestation.  
Through the study of literature we found several mRNA transcripts, which were expressed in the 
placenta and fetus. Some transcripts were better described than others as to why it is difficult to 
deduce which mRNA transcripts is the most promising in regard to an early diagnosis of pre-eclampsia 
and IUGR using feto-placental biomarkers in maternal blood. Extensive studies have to be performed 
in regards to the various placental transcripts in the maternal blood circulation but most importantly 
an optimal method of extraction of the fetal mRNA has to be further investigated. If this quantitative 
method should be applied clinically it is important that it can be automated to save time and thereby 
money. 
However, there are also ethical aspects of using this kind of method in screening for pre-eclampsia and 
IUGR early in pregnancy. Many otherwise healthy pregnancies will be sickened if all pregnant women 
are to be additionally screened. However, as mentioned before, many extensive studies have to be 
performed before this screening method will become an actual method of diagnosing pregnancy-
related disorders. 
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The studies of the levels of fetal mRNA in maternal blood are not only important in developing a new 
method of diagnosing pregnancy disorders. They are also important in regards to give a better 
understanding of the pathology and etiology of these disorders. 
 
3.3 Conclusion 
Through literature study we can conclude that many mRNA transcripts associated with placental and 
fetal development have been identified. When speaking of fetal or placental mRNAs in the maternal 
blood circulation few have been studied as being correlated to pre-eclampsia and IUGR. However, 
several of the mRNAs expressed in the placenta or fetus are likely to have some sort of association to 
these two complex disorders. 
In regards to whether whole blood or plasma provides the best sensitivity this has to be further 
resolved. From our experimental studies we could conclude that the one-step rtRT-PCR is preferable 
and more practical if applied to the clinic. The “PureLink Total RNA Blood Purification Kit” 
(Invitrogen) was furthermore the most successful in our studies to extract the total RNA from whole 
blood. However, methods used in other studies have also been effective. 
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5 Appendix  
5.1 Real-Time Reverse Transcription PCR (rtRT-PCR) 
Real time reverse transcription PCR (rtRT-PCR) is also refered to as real time PCR or quantitative reverse 
transcription PCR. The principles of real time PCR is genuine the same as in the conventional PCR. 
However, real time PCR is a method of quantifying mRNA 
transcripts. Hence, the amount of PCR product is 
quantified after each cycle (gene technology, 2008).  
When performing the PCR reaction the mRNA has to be 
transcribed into cDNA. This is done by reverse 
transcription using a sequence specific primer. Two 
primers is needed, one which is complementary to the 5’ 
end and one complementary to the 3’ end of the RNA 
sequence. Furthermore, a reverse transcriptase DNA 
polymerase, dNTP’s5 and a buffer solution are needed. 
The buffer solution will provide the suitable chemical 
environment so the DNA polymerase can perform 
maximum activity and stability. In addition, Mg2+ has to 
be provided, as it is a cofactor used by the DNA 
polymerase.   
When cDNA has been made, the three typical PCR steps 
are performed: denaturation, annealing and elongation 
as showed in  
 
figure 5.1.1: Picture of the one PCR cycle. 1) Denaturing  
the DNA strand at 94-96˚C. 2) Annealing at 65˚C 
.3) Elongation of the DNA strand at 72˚C (PCR, 2008). 
 
 
 
 
                                                          
5  dNTP = deoxynucleoside triphosphate, the building blocks used to synthesize the new DNA strand.  
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The first step is the denaturing step, where the reaction is heated to a temperature of 94-98˚C in about 
half a minute. This causes melting of the cDNA template and primers and thereby providing single 
strands of DNA. Hereafter, the annealing step is performed by lowering the temperature to about 50-65˚C. 
The temperature in this step is usually regulated so it is 3-5˚C lower than the Tm6 values of the primers. 
This allows the primers to anneal to the cDNA template and the DNA polymerase binds to the primer-
template hybrid so the DNA synthesis can begin. After this step, the temperature is increased to 70-80˚C 
(typically 72˚C), depending on the DNA polymerase used, making the final step of amplification: the 
elongation step.  This is the step, where the DNA polymerase synthesizes a new DNA strand 
complementary to the template cDNA strand. The dNTP’s added in by the DNA polymerase in a 5’ to 3’ 
direction.  
When the three steps have been performed it is termed a cycle. Usually, the PCR consists of about 45 
cycles. The same components are needed in the conventional PCR as those in the reverse transcription; 
however, the Reverse Transcriptase DNA polymerase is exchanged with a “conventional” DNA 
polymerase, such as the Taq polymerase. As real time PCR is a quantitative analysis it is based upon 
measuring fluorescence so the intensity of the fluorescence is proportional to the amount of PCR product. 
Therefore, a probe marked with a fluorescence molecule is needed. The probe is complementary to the 
cDNA molecule that is wished to be quantified. In our experiments we use a TaqMan probe, which is 
marked with a fluorophore (a fluorescent reporter, FAM in our case) in the 5’ end and with a quencer in 
the 3’ end (a Blach Hole Quencher (BHQ) in our case), figure 5.1.2 below. The close proximity between the 
fluorophore and the quencher, when attached to the probe, inhibits the fluorescence of the fluorophore. 
But when the DNA polymerase meets the TaqMan-probe, the probe will be hydrolyzed and removed; 
hence, fluorescence from the fluorophore can be registered because the fluorophore and quencher now 
are far apart, as depicted in figure 5.1.2. 
                                                          
6  The Tm value refers to the temperature at which half of the primers/probe is still attached to the template. The Tm 
is dependent on the nucleotides and the length of the oligonucleotides/probe.  
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figure 5.1.2: The figure shows how the TaqMan probe is used in real-time PCR (TaqMan probe, 2008).  
 
Analysis of real-time PCR 
A perfect amplification curve from the LightCycler480 real time PCR instrument from Roche is depicted 
below in figure 5.1.3 
 
figure 5.1.3: An amplification curve from the LightCycler480 real time PCR instrument by Roche (Operator’s 
Manual, 2008).  
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The perfect amplification of PCR-product would be two, as every PCR product is replicated by two in each 
cycle. This is not a realistic assumption as numerous factors influence the real-time PCR experiment, 
which is why the efficiency is not perfect. Thus, the amount of molecules (Tn) at cycle n, can be calculated 
using the following equation: 
Tn = T0 x En 
T0 is the initial number of target molecules, n is the number of cycles and E is the efficiency of the 
amplification.  
When the fluorescent registered is greater than the background noise, the amplification curves is 
depicted as above in figure 5.1.3  The point where the fluorescence of sample rises above the background 
noise is referred to as the “crossing point” (Cp) of the sample. Thus, this is the point at which the amplified 
PCR product is first visible. The Cp is dependent of the concentration of cDNA in the sample and therefore, 
a sample with a low concentration of cDNA requires several more amplification cycles than a sample with 
high concentration of cDNA. Thus, the earlier the signal rises in regards to cycles, the more RNA is in the 
sample.  
To calculate the initial concentration of cDNA (RNA) in the samples, serial dilutions of standard samples 
with a known concentration of a synthetic DNA standard oligo are made.  This is further used in 
calculating a standard curve, from where it is possible to calculate the initial concentration of the RNA 
with an otherwise unknown concentration.  In the standard curve the log of the initial standard 
concentrations are plotted against the Cp values of the samples. 
The slope of the standard curve represents the kinetics of the PCR amplification and is also referred to as 
the efficiency of the amplification curve. Thereby, it indicates how fast the amount of target nucleic acids 
can be expected to increase with the amplification cycles. The efficiency is calculated by the computer 
program provided by Roche and calculates the initial concentration of the samples using the equation 
stated earlier (Operator’s Manual, 2008).  
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5.2 Laboratory protocols and materials 
This section contains the protocols and the materials we used. Each of the four experiments we performed 
is outlined in the beginning and in the end the primers and probes we used as part of the real time RT-
PCR are outline. For further explanation of real time RT-PCR, see appendix 5.1 
 
Experiment 1: Real Time RT-PCR based on the mRNA of GAPDH 
from nucleated cells in maternal whole blood 
 
The purpose of this experiment was to extract total RNA from whole blood in one non pregnant 
female and one male. Additionally by using a two-step RT-PCR kit make GAPDH cDNA and thereafter 
amplify it using a real time RT-PCR instrument.   
 
Total RNA extraction: 
Kit used: Cells-to-CT Kit (Applied Biosystems / Ambion) 
 
Always use plastic tubes, pipettes etc! Always wear gloves! Always avoid RNAse contamination. 
 
Collection of blood samples and lysis of red blood cells: 
1. Two blood samples are taken from each person. Two small EDTA-tubes. One tube is for counting 
the total number of leukocytes per mL; the other tube is used for extraction of total RNA. It is 
necessary to know the number of leukocytes in the samples as it is limited how few and how many 
cells, and thereby how much RNA, one can make cDNA of.    
2. In tube number one leukocytes are counted in an ADVIA instrument. 
3. From the second blood tube a volume of blood corresponding to 100.000 leukocytes (10-50 ul of 
whole blood) is pipetted into a DNAse/RNAse-free Eppendorf-tube.  
NB! A serial dilution of the number of cells per reaction should be made: For example 
volumes corresponding to 200.000, 100.000, 50.000 and 10.000 cells.  
4. 5 volumes of Lysis Buffer (L5 from the “PureLink Total RNA Blood Purification Kit catno K1560-
01 Invitrogen) are added to 1 volume of fresh whole blood. 
5. Incubate for 10 minutes on ice. Vortex the tube briefly 2-3 times during the incubation step to 
allow complete lysis of erythrocytes. The solution turns translucent.  
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6. Centrifuge the Eppendorf tube a 4 °C at 400x for 10 minutes. Remove the supernatant completely 
and discard the supernatant. The pellet contains the leukocytes! Place cells on ice. 
 
The rest of the procedure uses reagents from the “TaqMan Gene Expression Cells-to-CT Kit” (Cat. No. 
AM1728 Applied Biosystems): 
 
Cell lysis: 
7. Thaw Stop Solution, invert or flick the tube several times to mix thoroughly (do not vortex), and 
place on ice. 
8. Dilute 10xPBS (pH 7.4) (Applied Biosystems catno AM9624) to 1xPBS with Nuclease-free Water 
(not DEPC-treated) (Applied Biosystems catno AM9937). Pour some of the 10xPBS into a plastic-
tube and pipette from this aliquot. Do not place anything in the original 10xPBS bottle!! 
9. Chill 1xPBS to 4°C. 
10. Wash cells in cold (4 °C) 1xPBS by resuspending them in 100 ul 1xPBS. Gently pellet the cells by 
centrifuge at 4 °C at 400x for 10 minutes. Aspirate and discard as much of the PBS as possible 
without disturbing the cell pellet. Place the cells on ice. 
11. Resuspend the cells in fresh, cold 1xPBS so that 5 ul will contain the desired number of cells for a 
single lysis reaction. 
12. For each sample mix in a DNAse/Rnase-free Eppendorf-tube 49.5 ul Lysis Solution and 0.5 ul 
Dnase I. Make a master mix for the required number of samples! 
13. Add 50 ul Lysis Solution with Dnase I to each cell sample. Mix the lysis reaction by pipetting up 
and down 5 times. (To avoid bubble formation, mix with the pipettor set at 35 ul and expel the 
solution without emptying the pipette tip completely). 
14. Incubate the lysis reactions for 5 min at room temperature (19-25°C). 
15. Pipet 5 ul Stop Solution directly into each lysis reaction. (Do this by touching the surface of the 
lysate with the opening of the pipet tip. This helps to ensure that all of the Stop Solution is mixed 
into the lysate). 
16. Mix the lysis reaction by pipetting up and down 5 times. (To avoid bubble formation, mix with the 
pipettor set at 35 ul and expel the solution without emptying the pipette tip completely). 
17. Incubate for 2 min at room tem (19-25°C). (Do not allow Cells-to-CT lysates to remain at room 
temp for longer than 20 min after adding the Stop Solution). 
 
Lysates can be stored on ice for up to 2 hr, or at –20 °C or –80 °C for up to 2 months. 
Reverse Transcription (RT): 
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18. Calculate the number of RT reactions in the experiment. Using the tables below, assemble an RT 
master mix for all the reactions (plus 1-2 reactions overage) in a nuclease-free Eppendorf tube on 
ice. As a start 20 ul or 10 ul of each lysate is used (can be up to 45% of the RT reaction; adjust the 
volume of Nuclease-free Water accordingly). 
 
A) 
Component Each reaction For 9 reactions 
2x RT Buffer 25 ul 225 
20x RT Enzyme Mix 2.5 ul 22,5 
Nuclease-free Water 2.5 ul 22,5 
Final volume RT master mix 30 ul 270 
 
B) 
Component Each reaction For  9 reactions 
2x RT Buffer 25 ul 225 
20x RT Enzyme Mix 2.5 ul 22,5 
Nuclease-free Water 12.5 ul 112,5 
Final volume RT master mix 40 ul 360 
 
19. For both (A) and (B) one minus-RT control tube is set up; use Nuclease-free Water in place of 20x 
RT Enzyme Mix. 
20. Distribute 30 or 40 ul RT Master Mix to nuclease-free Eppendorf tubes. 
21. Add sample lysate to each aliquot of RT master mix for a final 50 ul reaction volume. 
22. Once assembled, mix reactions gently, then centrifuge briefly to collect the contents at the bottom 
of the reaction vessel. 
23. Using a thermal block, incubate at 37 °C for 60 min, then at 95 °C for 5 min to inactivate RT 
enzyme. Set the RT reactions at 4-8 °C immediately, and if not used in 1-2 hrs then store them 
quickly after at -20 °C. 
Completed RT reactions may be stored at –20 °C. 
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Real-Time RT-PCR: 
GAPDH-cDNA sequence 
 
1. Mix the following rt-RT-PCR reagents (remember negative PCR control (only water)): 
 
A 
Component Per reaction For   18   reactions  
Nucelase-free Water 20 ul 360      
GAPDH-forw primer (10 pmol/ul) 2.5 ul 45 
GAPDH-rev primer (10 pmol/ul) 2.5 ul 45 
Pr2GAPDHfam probe (4 pmol/ul) 2.5 ul 45 
TaqMan Gene Expression Assay (20x) 2.5 ul 45 
Final Master Mix Volume 30 ul 540 ul 
 
B 
Component Per reaction For   18   reactions  
Nucelase-free Water 30 ul 540                
GAPDH-forw primer (10 pmol/ul) 2.5 ul 45 
GAPDH-rev primer (10 pmol/ul) 2.5 ul 45 
Pr2GAPDHfam probe (4 pmol/ul) 2.5 ul 45 
TaqMan Gene Expression Assay (20x) 2.5 ul 45 
Final Master Mix Volume 40 ul 720 ul 
 
2. Distribute the PCR master mix into individual PCR wells at room temp. 
3. Add a portion of the RT reaction (cDNA sample) to each aliquot of PCR master mix so the total 
volume will be 50 ul (20 ul in A and 10 ul in B ). See the scheme after this protocol to see the 
distribution of all the samples into the PCR wells. 
4. Cover the plate and mix gently. Then centrifuge to remove bubbles and collect the contents at the 
bottom of the wells/tubes. 
5. Place the reactions in a real-time PCR instrument (we used an LightCycler®480 System from 
Roche) and start the run using the following settings: 
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PCR program: 
Multi Color Hydrolysis Probes     50 ul 
Fluorescent: FAM Probe 
 
  Cycles Analysis Mode 
Reverse Transcription: 1 none 
Pre-incubation:  1 none 
Amplification: 50  Quantification 
Cooling:  1 None 
Reverse Transcription: 48 °C 30 min 4.4 C/s 
Pre-incubation:  95 °C 10 min 4.4 C/s 
Amplification: 
95 °C 15 sek 4.4 C/s  
60 °C 60 sek         2.2 C/ 
 72 °C 1 sek 4.4 C/s  
Cooling:    40 °C 10 sek 2 C/s 
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Experiment 2: Real Time PCR based on GAPDH mRNA from 
nucleated cell from whole blood 
 
Total RNA extraction: 
Kit used: PureLink Total RNA Blood Purification Kit (Invitrogen / catno K1560-01) 
 
Always use plastic tubes, pipettes etc! Always wear gloves! Always avoid RNAse 
contamination. 
 
 
Regarding Lysis Buffer (L3) and maybe some of the other buffers: Contain guanidine 
isothiocyanate. Do not add bleach or acidic solutions directly to solutions containing 
guanidine isothiocyanate; this may form reactive compounds and toxic gases when mixed 
with bleach or acids. Wear a laboratory coat, disposable gloves, and eye protection when 
handling solutions containing this chemical, or use a fume cupboard.   
 
 70% ethanol has to be prepared from absolute ethanol using Rnase-free water. 
 Wash Buffer (W5): Add 40 ml 96-100% ethanol to 10 ml Wash Buffer (W5) 
included in the kit. Store the Wash Buffer (W5) with ethanol at room temperature. 
 For each sample prepare the following Dnase I mix: 
o 10x DNase I Buffer   10 ul 
o Dnase I (catno 18068-015 Invitrogen) 10 units 
o Rnase-free water   to 100 ul in total 
Mix the contents. 
 
Procedure: 
1. Two blood samples are taken from each person. One EDTA-tube from one person, and 
one heparin tube from the other person.  
2. From each blood tube a volume of 500 ul or 250 ul of whole blood is pipetted into a 
DNAse/RNAse-free 10 or 15 ml-tube.  
3. 5 volumes of Lysis Buffer (L5 from the “PureLink Total RNA Blood Purification Kit 
catno K1560-01 Invitrogen) are added to 1 volume of fresh whole blood (2.5 ml or 1.25 
ml). 
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4. Incubate for 10 minutes on ice. Vortex the tube briefly 2-3 times during the incubation 
step to allow complete lysis of erythrocytes. The solution turns translucent.  
5. Centrifuge the Eppendorf tube a 4 °C at 400x for 10 minutes. Remove the supernatant 
completely and discard the supernatant. The pellet contains the leukocytes!  
6. Resuspend the leukocyte pellet in 2 volumes of Lysis Buffer (L5) (1 ml and 500 ul). Mix 
well by vortexing briefly. 
7. Centrifuge the Eppendorf tube a 4 °C at 400x for 10 minutes. Remove the supernatant 
completely and discard the supernatant. The pellet contains the leukocytes! (The 
leukocyte pellet should be white with no traces of red. If the pellet is significantly red, 
wash the pellet with Lysis Buffer (L5)). 
8. Resuspend the leukocyte pellet in 350 ul Lysis Buffer (L3). Mix well by vortexing briefly 
to completely resuspend the pellet ensuring the absence of any cell clumps. 
9. Add 350 ul 70% ethanol to the tube and mix well by vortexing briefly. 
10. Remove a Spin Cartridge in a Collection Tube from the package. Transfer the leukocyte 
lysate from Step 9 to the Spin Cartridge. 
11. Centrifuge the Spin Cartridge at 8,000 x g for 1 minute at room temperature. 
12. Discard the flow through (in a separate waste tube) and place the Spin Cartridge into 
the collection tube. 
13. Add 700 ul of Wash Buffer (W4) supplied in the kit to the Spin Cartridge. 
14. Centrifuge the Spin Cartridge at 8,000 x g for 30 seconds at room temperature. 
15. To remove genomic DNA from the samples, add 100 ul of DNase I solution to the Spin 
Cartridge. Incubate at room temperature for 15 minutes. 
16. Add 500 ul of Wash Buffer (W4) to the Spin Cartridge. Incubate for 5 minutes at room 
temperature. 
17. Centrifuge the Spin Cartridge at 8,000 x g for 30 seconds at room temperature. Discard 
the flow through but place the Spin Cartridge into the collection tube again. 
18. Add 500 ul of Wash Buffer (W5) with ethanol added to the Spin Cartridge. 
19. Centrifuge the Spin Cartridge at 8,000 x g for 30 seconds at room temperature. 
20. Centrifuge the Spin Cartridge at 8,000 x g for 30 seconds at room temperature (not a 
mistake!). 
21. Discard the flow through and place the Spin Cartridge into the Wash Tube supplied 
with the kit and centrifuge the Spin Cartridge at 8,000 x g for 1 minute at room 
temperature to remove any residual Wash Buffer (W5). 
22. Place the Spin Cartridge in a clean 1.7-ml Elution Tube supplied with the kit. 
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23. Add 40 ul of sterile, RNase-free water (supplied with the kit) to the center of the 
cartridge. 
24. Incubate at room temperature for 1 minute. Centrifuge the Spin Cartridge at 8,000 x g 
for 1 minute at room temperature. 
25. The elution contains purified total RNA. Remove and discard the cartridge. 
26. Store the total RNA at –80 °C. 
The total RNA will be used in a one-step real-time PCR kit from Roche. 
 
Real-Time RT-PCR: 
Kit used: One-Step RT-PCR: LightCycler480 RNA Master Hydrolysis Probes (Roche catno 
04991885001) 
 
Amplified sequence: GAPDH 
 
1. Mix the following rt-RT-PCR reagents (remember negative PCR control (only water)): 
 
A) 
Component Per reaction For    6      reactions  
Nucelase-free Water (colorless)  2.75 ul  16.5 ul                 
GAPDH-forw primer (10 pmol/ul)   2.5 ul  15 ul 
GAPDH-rev primer (10 pmol/ul)   2.5 ul  15 ul 
Pr2GAPDHfam probe (4 pmol/ul)   3.0 ul  18 ul 
Activator (green)   3.25 ul  19.5 ul 
LightCycler480 RNA Master 2.7x (red) 18.5 ul 111 ul 
Enhancer, 20x (yellow)   2.5 ul  15 ul 
Final Master Mix Volume 35 ul 210 ul 
 
B) 
Component Per reaction For    6      reactions  
Nucelase-free Water (colorless)  7.75 ul  46.5 ul            
GAPDH-forw primer (10 pmol/ul)   2.5 ul  15 ul 
GAPDH-rev primer (10 pmol/ul)   2.5 ul  15 ul 
Pr2GAPDHfam probe (4 pmol/ul)   3.0 ul  18 ul 
Activator (green)   3.25 ul  19.5 ul 
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LightCycler480 RNA Master 2.7x (red) 18.5 ul 111 ul 
Enhancer, 20x (yellow)   2.5 ul  15 ul 
Final Master Mix Volume 40 ul 240 ul 
 
C) 
Component Per reaction For    6      reactions  
Nucelase-free Water (colorless)  12.75 ul  76.5 ul                 
GAPDH-forw primer (10 pmol/ul)   2.5 ul  15 ul 
GAPDH-rev primer (10 pmol/ul)   2.5 ul  15 ul 
Pr2GAPDHfam probe (4 pmol/ul)   3.0 ul  18 ul 
Activator (green)   3.25 ul  19.5 ul 
LightCycler480 RNA Master 2.7x (red) 18.5 ul 111 ul 
Enhancer, 20x (yellow)   2.5 ul  15 ul 
Final Master Mix Volume 45 ul 270 ul 
 
D) Control with no enzymes in, control of genomic DNA 
Component Per reaction For    6      reactions 
Nucelase-free Water 12 ul  72 ul              
2x LC480 Probes Master 25 ul 150 ul 
GAPDH-forw primer (10 pmol/ul) 2.5 ul   15 ul 
GAPDH-rev primer (10 pmol/ul) 2.5 ul   15 ul 
Pr2GAPDHfam probe (4 pmol/ul) 3.0 ul   18 ul 
Final Master Mix Volume 45 ul 270 ul 
 
E) Testing the cDNA made from experiment 1 
Component Per reaction For     18     reactions  
Nucelase-free Water  7 ul 126 ul                
2x LC480 Probes Master 25 ul 450 ul 
GAPDH-forw primer (10 pmol/ul) 2.5 ul  45 ul 
GAPDH-rev primer (10 pmol/ul) 2.5 ul  45 ul 
Pr2GAPDHfam probe (4 pmol/ul) 3.0 ul  54 ul 
Final Master Mix Volume 40 ul 720 ul 
 
2. Distribute the PCR master mix into individual PCR wells at room temp.  
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3. For A-C: Add a portion of the total RNA from the PureLink-extraction to each aliquot of 
PCR master mix (15 ul to A, 10 ul to B and E, and 5 ul to C and D ).  
4. For D: Add 5 ul of the total RNA from the PureLink-extraction to each aliquot of PCR 
master mix).  
5. For E: Add 10 ul of the RT reaction (cDNA sample) to each aliquot of PCR master mix. 
See the scheme after this protocol to see the distribution of all the samples into the PCR 
wells. 
6. Cover the plate and mix gently. Then centrifuge to remove bubbles and collect the 
contents at the bottom of the wells/tubes. 
7. Place the reactions in a real-time PCR instrument (we used ) and start the run using 
the following settings: 
 
PCR program: 
Multi Color Hydrolysis Probes     50 ul 
Fluorescent: FAM Probe 
  Cycles Analysis Mode 
Reverse Transcription: 1 none 
Pre-incubation:  1 none 
Amplification: 45 Quantification 
Cooling:  1 None 
Reverse Transcription: 61 °C 3 min 4.4 C/s 
Pre-incubation:  95 °C 30 sek 4.4 C/s 
Amplification: 
95 °C 15 sek 4.4 C/s  
60 °C 60 sek         2.2 C/s  
72 °C 1 sek 4.4 C/s 
Cooling:   40 °C 10 sek 2 C/s
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Experiment 3: Real Time PCR based on specific RNA sequences 
from nucleated cells from whole blood 
RNA extraction: 
Kit used: PureLink Total RNA Blood Purification Kit (Invitrogen / catno K1560-01)  
Procedure: 
1. One blood sample is taken from some pregnant women in EDTA tubes. 
2. From each blood tube a volume of 500 ul or 250 ul of whole blood is pipetted into a 
DNAse/RNAse-free 10 or 15 ml-tube (we used 15 ml-tubes).  
3. 5 volumes of Lysis Buffer (L5 from the “PureLink Total RNA Blood Purification Kit catno K1560-
01 Invitrogen) are added to 1 volume of fresh whole blood (2.5 ml or 1.25 ml). 
4. Incubate for 10 minutes on ice. Vortex the tube briefly 2-3 times during the incubation step to 
allow complete lysis of erythrocytes. The solution turns translucent.  
5. Centrifuge the Eppendorf tube a 4°C at 400x for 10 minutes. Remove the supernatant completely 
and discard the supernatant. The pellet contains the leukocytes!  
6. Resuspend the leukocyte pellet in 2 volumes of Lysis Buffer (L5) (1 ml and 500 ul). Mix well by 
vortexing briefly. 
7. Centrifuge the Eppendorf tube a 4°C at 400x for 10 minutes. Remove the supernatant completely 
and discard the supernatant. The pellet contains the leukocytes! (The leukocyte pellet should be 
white with no traces of red. If the pellet is significantly red, wash the pellet with Lysis Buffer (L5)). 
8. Resuspend the leukocyte pellet in 350 ul Lysis Buffer (L3). Mix well by vortexing briefly to 
completely resuspend the pellet ensuring the absence of any cell clumps. 
9. Add 350 ul 70% ethanol to the tube and mix well by vortexing briefly. 
10. Remove a Spin Cartridge in a Collection Tube from the package. Transfer the leukocyte lysate 
from Step 9 to the Spin Cartridge. 
11. Centrifuge the Spin Cartridge at 8,000 x g for 1 minute at room temperature. 
12. Discard the flow through (in a separate waste tube) and place the Spin Cartridge into the 
collection tube. 
13. Add 700 ul of Wash Buffer (W4) supplied in the kit to the Spin Cartridge. 
14. Centrifuge the Spin Cartridge at 8,000 x g for 30 seconds at room temperature. 
15. To remove genomic DNA from the samples, add 100 ul of DNase I solution to the Spin Cartridge. 
Incubate at room temperature for 15 minutes. 
16. Add 500 ul of Wash Buffer (W4) to the Spin Cartridge. Incubate for 5 minutes at room 
temperature. 
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17. Centrifuge the Spin Cartridge at 8,000 x g for 30 seconds at room temperature. Discard the flow 
through but place the Spin Cartridge into the collection tube again. 
18. Add 500 ul of Wash Buffer (W5) with ethanol added to the Spin Cartridge. 
19. Centrifuge the Spin Cartridge at 8,000 x g for 30 seconds at room temperature. 
20. Centrifuge the Spin Cartridge at 8,000 x g for 30 seconds at room temperature (not a mistake!). 
21. Discard the flow through and place the Spin Cartridge into the Wash Tube supplied with the kit 
and centrifuge the Spin Cartridge at 8,000 x g for 1 minute at room temperature to remove any 
residual Wash Buffer (W5). 
22. Place the Spin Cartridge in a clean 1.7-ml Elution Tube supplied with the kit. 
23. Add 50 ul of sterile, RNase-free water (supplied with the kit) to the center of the cartridge. 
24. Incubate at room temperature for 1 minute. Centrifuge the Spin Cartridge at 8,000 x g for 1 
minute at room temperature. 
25. The elution contains purified total RNA. Remove and discard the cartridge. 
26. Store the total RNA at –80°C. 
The total RNA will be used in a one-step real-time PCR kit from Roche. 
 
Real-Time RT-PCR:  
Kit used: One-Step RT-PCR: LightCycler480 RNA Master Hydrolysis Probes (Roche catno 04991885001) 
 Amplified sequences:  GAPDH   
Βeta-hCG  
HLA-G  
CRH   
Beta-hCG/genomic DNA control 
 
1. Mix the following rt-RT-PCR reagents (remember negative PCR control (only water)): 
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A) GAPDH 
Component Per reaction For    30      reactions  
Nucelase-free Water (colorless)  10.75 ul  322.5 ul                 
GAPDH-forw primer (10 pmol/ul)   2.5 ul     75  ul 
GAPDH-rev primer (10 pmol/ul)   2.5 ul     75 ul 
Pr2GAPDHfam probe (4 pmol/ul)   3.0 ul     90 ul 
Activator (green)   3.25 ul     97.5 ul 
LightCycler480 RNA Master 2.7x (red) 18.5 ul   555 ul 
Enhancer, 20x (yellow)   2.5 ul     75 ul 
Final Master Mix Volume 43 ul 1290 ul 
 
B) Beta-hCG 
Component Per reaction For    20      reactions  
Nucelase-free Water (colorless)  10.75 ul  215 ul            
BhCG-forw primer (10 pmol/ul)   2.5 ul    50 ul 
BhCG-rev primer (10 pmol/ul)   2.5 ul    50 ul 
BhCG-hydro probe (4 pmol/ul)   3.0 ul    60 ul 
Activator (green)   3.25 ul    65 ul 
LightCycler480 RNA Master 2.7x (red) 18.5 ul  370 ul 
Enhancer, 20x (yellow)   2.5 ul    50 ul 
Final Master Mix Volume 43 ul 860 ul 
 
C) HLA-G 
Component Per reaction For    20      reactions  
Nucelase-free Water (colorless)  13.25 ul  265 ul                 
HLAG-ex3 forw primer (10 pmol/ul)   2.5 ul    50 ul 
HLAG-ex4rev primer (10 pmol/ul)   2.5 ul    50 ul 
Universal Probe #77 (10 uM)   0.5     10 ul    
Activator (green)   3.25 ul    65 ul 
LightCycler480 RNA Master 2.7x (red) 18.5 ul  370 ul 
Enhancer, 20x (yellow)   2.5 ul    50 ul 
Final Master Mix Volume 43 ul 860 ul 
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D) CRH 
Component Per reaction For    8      reactions  
Nucelase-free Water (colorless) 10.75 ul   86 ul            
CRH-forw primer (10 pmol/ul)   2.5 ul    20 ul 
CRH-rev primer (10 pmol/ul)   2.5 ul    20 ul 
CRH-hydro probe (4 pmol/ul)   3.0 ul    24 ul 
Activator (green)   3.25 ul    26 ul 
LightCycler480 RNA Master 2.7x (red) 18.5 ul  148 ul 
Enhancer, 20x (yellow)   2.5 ul    20 ul 
Final Master Mix Volume 43 ul 344 ul 
 
E) Control for genomic DNA / beta-hCG 
Component Per reaction For     8     reactions  
Nucelase-free Water 10 ul   80 ul                
2x LC480 Probes Master  25 ul 200 ul 
BhCG-forw primer (10 pmol/ul) 2.5 ul   20 ul 
BhCG-rev primer (10 pmol/ul) 2.5 ul   20 ul 
BhCG-hydro probe (4 pmol/ul) 3.0 ul   24 ul 
Final Master Mix Volume 43 ul 344 ul 
 
 
2. Distribute the PCR master mix into individual PCR wells at room temp. 
3. Add 7 ul of the total RNA from the PureLink-extraction to each aliquot of PCR master mix. 
4. For standards: Add 5 ul of diluted standard plus 2 ul of water to each aliquot of PCR master mix. 
See the scheme after this protocol to see the distribution of all the samples into the PCR wells. 
5. Cover the plate and mix gently. Then centrifuge to remove bubbles and collect the contents at the 
bottom of the wells/tubes. 
6. Place the reactions in a real-time PCR instrument (we used) and start the run using the following 
settings: 
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PCR program: 
Multi Color Hydrolysis Probes     50 ul 
Fluorescent: FAM Probe 
 
  Cycles Analysis Mode 
Reverse Transcription: 1 none 
Pre-incubation:  1 none 
Amplification: 50 Quantification 
Cooling:  1 None 
Reverse Transcription: 61  °C 3 min 4.4 C/s 
Pre-incubation:  95  °C 30 sek 4.4 C/s 
Amplification: 
95  °C 15 sek 4.4 C/s  
60  °C 60 sek         2.2 C/s  
72  °C 1 sek 4.4 C/s  
Cooling:  40 C 10 sek 2 C/s 
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Experiment 4: Real Time PCR based on specific RNA sequences 
from nucleated cells from whole blood 
 
RNA extraction: 
Used Kit: PureLink Total RNA Blood Purification Kit (Invitrogen / catno K1560-01)  
 
Blood samples: 
 2 from pregnant women (week 19-20) 
 2 from non-pregnant blood donors (serum-hCG is also measured) 
 1 from a male 
 
 Total RNA is extracted from all these 5 samples the usual way (with red cell lysis). 
 Total RNA is also extracted from samples from the 2 pregnant women and 1 non-pregnant 
woman WITHOUT red cell lysis.  
 
Procedure without red cell lysis: 
 From each blood tube a volume of 500 ul of whole blood is pipetted into a DNAse/RNAse-free 
10 or 15 ml-tube (we used 15 ml-tube).  
 Centrifuge the Eppendorf tube at RT at 4000g for 10 minutes. Remove the supernatant 
completely and discard the supernatant. The pellet contains the cells.  
 Resuspend the cell pellet in 2 ml of 1xPBS buffer. 
 Centrifuge the Eppendorf tube at RT at 4000g for 10 minutes. Remove the supernatant 
completely and discard the supernatant. The pellet contains the cells. 
 Proceed from step 8 below. 
 
Procedure with red cell lysis: 
24. One blood sample is taken from each person (EDTA-tube).  
25. From each blood tube a volume of 500 ul of whole blood is pipetted into a DNAse/RNAse-free 10 
or 15 ml-tube.  
26. 5 volumes of Lysis Buffer (L5 from the “PureLink Total RNA Blood Purification Kit catno K1560-
01 Invitrogen) are added to 1 volume of fresh whole blood (2.5 ml or 1.25 ml). 
27. Incubate for 10 minutes on ice. Vortex the tube briefly 2-3 times during the incubation step to 
allow complete lysis of erythrocytes. The solution turns translucent.  
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28. Centrifuge the Eppendorf tube a 4 °C at 400g for 10 minutes. Remove the supernatant completely 
and discard the supernatant. The pellet contains the leukocytes!  
29. Resuspend the leukocyte pellet in 2 volumes of Lysis Buffer (L5) (1 ml and 500 ul). Mix well by 
vortexing briefly. 
30. Centrifuge the Eppendorf tube a 4 °C at 400g for 10 minutes. Remove the supernatant completely 
and discard the supernatant. The pellet contains the leukocytes! (The leukocyte pellet should be 
white with no traces of red. If the pellet is significantly red, wash the pellet with Lysis Buffer (L5)). 
31. Resuspend the leukocyte pellet in 350 ul Lysis Buffer (L3). Mix well by vortexing briefly to 
completely resuspend the pellet ensuring the absence of any cell clumps. 
32. Add 350 ul 70% ethanol to the tube and mix well by vortexing briefly. 
33. Remove a Spin Cartridge in a Collection Tube from the package. Transfer the leukocyte lysate 
from Step 9 to the Spin Cartridge. 
34. Centrifuge the Spin Cartridge at 8,000 x g for 1 minute at room temperature. 
35. Discard the flow through (in a separate waste tube) and place the Spin Cartridge into the 
collection tube. 
36. Add 700 ul of Wash Buffer (W4) supplied in the kit to the Spin Cartridge. 
37. Centrifuge the Spin Cartridge at 8,000 x g for 30 seconds at room temperature. 
38. To remove genomic DNA from the samples, add 100 ul of DNase I solution to the Spin Cartridge. 
Incubate at room temperature for 15 minutes. 
39. Add 500 ul of Wash Buffer (W4) to the Spin Cartridge. Incubate for 5 minutes at room 
temperature. 
40. Centrifuge the Spin Cartridge at 8,000 x g for 30 seconds at room temperature. Discard the flow 
through but place the Spin Cartridge into the collection tube again. 
41. Add 500 ul of Wash Buffer (W5) with ethanol added to the Spin Cartridge. 
42. Centrifuge the Spin Cartridge at 8,000 x g for 30 seconds at room temperature. 
43. Centrifuge the Spin Cartridge at 8,000 x g for 30 seconds at room temperature (not a mistake!). 
44. Discard the flow through and place the Spin Cartridge into the Wash Tube supplied with the kit 
and centrifuge the Spin Cartridge at 8,000 x g for 1 minute at room temperature to remove any 
residual Wash Buffer (W5). 
45. Place the Spin Cartridge in a clean 1.7-ml Elution Tube supplied with the kit. 
46. Add 50 ul of sterile, RNase-free water (supplied with the kit) to the center of the cartridge. 
47. Incubate at room temperature for 1 minute. Centrifuge the Spin Cartridge at 8,000 x g for 1 
minute at room temperature. 
48. The elution contains purified total RNA. Remove and discard the cartridge. 
49. Store the total RNA at –80 °C. 
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The total RNA will be used in a one-step real-time PCR kit from Roche. 
 
Real-Time RT-PCR:  
Kit used: One-Step RT-PCR: LightCycler480 RNA Master Hydrolysis Probes (Roche catno 04991885001) 
 
Amplified sequences: GAPDH 
   Beta-hCG  
CRH  
CRH/genomic DNA control 
GAPDH/genomic DNA control 
 
1. Mix the following rt-RT-PCR reagents (remember negative PCR control (only water)): 
 
A) GAPDH 
Component Per reaction For    25      reactions  
Nucelase-free Water (colorless)  8.75 ul  218.75 ul                 
GAPDH-forw primer (10 pmol/ul)   2.5 ul     62.5  ul 
GAPDH-rev primer (10 pmol/ul)   2.5 ul     62.5 ul 
Pr2GAPDHfam probe (4 pmol/ul)   3.0 ul     75.0 ul 
Activator (green)   3.25 ul     81.25 ul 
LightCycler480 RNA Master 2.7x (red) 18.5 ul   462.5 ul 
Enhancer, 20x (yellow)   2.5 ul     62.5 ul 
Final Master Mix Volume 41 ul 1290 ul 
 
B) Beta-hCG 
Component Per reaction For    23      reactions  
Nucelase-free Water (colorless)  8.75 ul  201.25 ul            
BhCG-forw primer (10 pmol/ul)   2.5 ul    57.5 ul 
BhCG-rev primer (10 pmol/ul)   2.5 ul    57.5 ul 
BhCG-hydro probe (4 pmol/ul)   3.0 ul    69.0 ul 
Activator (green)   3.25 ul    74.75 ul 
LightCycler480 RNA Master 2.7x (red) 18.5 ul  425.5 ul 
Enhancer, 20x (yellow)   2.5 ul    57.5 ul 
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Final Master Mix Volume 41 ul 943 ul 
 
C) CRH 
Component Per reaction For    10      reactions  
Nucelase-free Water (colorless)   8.75 ul    87.5 ul            
CRH-forw primer (10 pmol/ul)   2.5 ul    25.0 ul 
CRH-rev primer (10 pmol/ul)   2.5 ul    25.0 ul 
CRH-hydro probe (4 pmol/ul)   3.0 ul    30.0 ul 
Activator (green)   3.25 ul    32.5 ul 
LightCycler480 RNA Master 2.7x (red) 18.5 ul  185.0 ul 
Enhancer, 20x (yellow)   2.5 ul    25.0 ul 
Final Master Mix Volume 41 ul 410 ul 
 
D) Control for genomic DNA / CRH 
Component Per reaction For     10     reactions  
Nucelase-free Water   8.0 ul   80 ul                
2x LC480 Probes Master  25.0 ul 250 ul 
CRH-forw primer (10 pmol/ul)   2.5 ul   25 ul 
CRH-rev primer (10 pmol/ul)   2.5 ul   25 ul 
CRH-hydro probe (4 pmol/ul)   3.0 ul   30 ul 
Final Master Mix Volume 41 ul 410 ul 
 
 
E) Control for genomic DNA / GAPDH 
Component Per reaction For     10     reactions  
Nucelase-free Water   8.0 ul   80 ul                
2x LC480 Probes Master  25.0 ul 250 ul 
GAPDH-forw primer (10 pmol/ul)   2.5 ul   25 ul 
GAPDH-rev primer (10 pmol/ul)   2.5 ul   25 ul 
Pr2GAPDHfam probe (4 pmol/ul)   3.0 ul   30 ul 
Final Master Mix Volume 41 ul 410 ul 
 
 
2. Distribute the PCR master mix into individual PCR wells at room temp. 
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3. Add 9 ul of the total RNA from the PureLink-extraction to each aliquot of PCR master mix. 
4. For standards: Add 5 ul of diluted standard plus 4 ul of water to each aliquot of PCR master mix. . 
See the scheme after this protocol to see the distribution of all the samples into the PCR wells. 
5. Cover the plate and mix gently. Then centrifuge to remove bubbles and collect the contents at the 
bottom of the wells/tubes. 
6. Place the reactions in a real-time PCR instrument and start the run using the following settings: 
 
 
PCR program: 
Multi Color Hydrolysis Probes     50 ul 
Fluorescent: FAM Probe 
  Cycles Analysis Mode 
Reverse Transcription: 1 none 
Pre-incubation:  1 none 
Amplification: 50 Quantification 
Cooling:  1 None 
Reverse Transcription: 61  °C 3 min 4.4 C/s 
Pre-incubation:  95  °C 30 sek 4.4 C/s 
Amplification: 
95  °C 15 sek 4.4 C/s  
60  °C 60 sek         2.2 C/s  
72  °C 1 sek 4.4 C/s  
5.2.1.1.1.1 Cooling:  40 C 10 sek 2 C/s 
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5 + 4 ul 
B1 
GAPDH 
Stan 106 
5 + 4 ul 
B2 
GAPDH 
Stan 107 
5 + 4 ul 
B3 
GAPDH 
Sampl 1 
9 ul 
B4 
GAPDH 
Sampl 2 
9 ul 
B5 
GAPDH 
Sampl 3 
9 ul 
B6 
GAPDH 
Sampl 4 
9 ul 
B7 
GAPDH 
Sampl 5 
9 ul 
B8 
GAPDH 
Sampl 6 
9 ul 
B9 
GAPDH 
Sampl 7 
9 ul 
B10 
GAPDH 
Sampl 8 
9 ul 
B11 
GAPDH 
Water 
9 ul 
B12 
 
C1 
B-hCG 
Stan 101 
5 + 4 ul 
C2 
B-hCG 
Stan 102 
5 + 4 ul 
C3 
B-hCG 
Stan 103 
5 + 4 ul 
C4 
B-hCG 
Stan 104 
5 + 4 ul 
C5 
B-hCG 
Stan 105 
5 + 4 ul 
C6 
B-hCG 
Stan 106 
5 + 4 ul 
C7 
B-hCG 
Stan 101 
5 + 4 ul 
C8 
B-hCG 
Stan 102 
5 + 4 ul 
C9 
B-hCG 
Stan 103 
5 + 4 ul 
C10 
B-hCG 
Stan 104 
5 + 4 ul 
C11 
B-hCG 
Stan 105 
5 + 4 ul 
C12 
B-hCG 
Stan 106 
5 + 4 ul 
D1 
B-hCG 
Sampl 1 
9 ul 
D2 
B-hCG 
Sampl 2 
9 ul 
D3 
B-hCG 
Sampl 3 
9 ul 
D4 
B-hCG 
Sampl 4 
9 ul 
D5 
B-hCG 
Sampl 5 
9 ul 
D6 
B-hCG 
Sampl 6 
9 ul 
D7 
B-hCG 
Sampl 7 
9 ul 
D8 
B-hCG 
Sampl 8 
9 ul 
D9 
B-hCG 
Water 
9 ul 
D10 
 
D11 
 
D12 
 
E1 
CRH 
Sampl 1 
9 ul 
E2 
CRH 
Sampl 2 
9 ul 
E3 
CRH 
Sampl 3 
9 ul 
E4 
CRH 
Sampl 4 
9 ul 
E5 
CRH 
Sampl 5 
9 ul 
E6 
CRH 
Sampl 6 
9 ul 
E7 
CRH 
Sampl 7 
9 ul 
E8 
CRH 
Sampl 8 
9 ul 
E9 
CRH 
Water 
9 ul 
E10 
 
E11 
 
E12 
 
F1 
CRH 
S1 DNA 
control 
9 ul 
F2 
CRH 
S2 DNA 
control 
9 ul 
F3 
CRH 
S3 DNA 
control 
9 ul 
F4 
CRH 
S4 DNA 
control 
9 ul 
F5 
CRH 
S5 DNA 
control 
9 ul 
F6 
CRH 
S6 DNA 
control 
9 ul 
F7 
CRH 
S7 DNA 
control 
9 ul 
F8 
CRH 
S8 DNA 
control 
9 ul 
F9 
CRH 
W DNA 
control 
9 ul 
F10 
 
F11 
 
F12 
 
G1 
GAPDH 
S1 DNA 
control 
9 ul 
G2 
GAPDH 
S2 DNA 
control 
9 ul 
G3 
GAPDH 
S3 DNA 
control 
9 ul 
G4 
GAPDH 
S4 DNA 
control 
9 ul 
G5 
GAPDH 
S5 DNA 
control 
9 ul 
G6 
GAPDH 
S6 DNA 
control 
9 ul 
G7 
GAPDH 
S7 DNA 
control 
9 ul 
G8 
GAPDH 
S8 DNA 
control 
9 ul 
G9 
GAPDH 
W DNA 
control 
9 ul 
G10 G11 G12 
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H1 
 
H2 
 
H3 
 
H4 
 
H5 
 
H6 
 
H7 
 
H8 H9 H10 H11 H12 
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Primers 
 
The different primers used in the experiments are outlined in this section. 
 
 
GAPDH assay: 
          Exon1  Exon 2 
5’ AA ggTCggAgTC AACggATTTggTCgT ATTgggCgCC TggTCACCAg ggCTgCTTTT AACTCTggTA  
  
AAgTggATAT TgTTgCCATC AATgA 3’ 
 
Primer 
Probe 
 
GAPDH ASSAY Tm value 
(˚C) 
Forward Primer   (Ex12GAPDH) 5’ AAg gTC ggA gTC AAC ggA TTT g 3’  63,5 
Reverse Primer (GAPDHrev) 5’ TCA TTg ATg gCA ACA ATA TCC ACT TTA CC3’  63,5 
Probe (TaqMan Probe: 
Pr2GADPHfam) 
5’ FAM- TTg ggC gCC Tgg TCA CCA ggg CTg CTT  -
BHQ  3’  
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Beta-hCG assay: 
 
  Exon 1    Exon 2 
5’ATggA gATgTTCCAg gggCTgCTgC TgTTgCTgCT gCTgAgCATg ggCgggACAT  
 
 
gggCATCCAA ggAgCCgCTT CggCCACggT gCCgCCCCAT CAATgCCACC CTggCTgTgg 
 
Forward: BhCG-forw → 
AgAAggAggg CTgCCCCgTg TgCATCACCg TCAACACCAC CATCTgTgCC ggCTACTgCC 
 
        Exon 2   Exon 3        TaqMan/hydrolyse probe (FAM): BhCG-hydro 
CCACCATgAC CCgCgTgCTg CAgggggTCC TgCCggCCCT gCCTCAggTg gTgTgCAACT 
 
      Reverse: bhCG-rev 
ACCgCgATgT gCgCTTCgAg TCCATCCggC TCCCTggCTg CCCgCgCggC gTgAACC….3’ 
 
(Exon 3 continues) 
 
Beta-hCG ASSAY Tm value 
(˚C) 
Forward Primer (BhCG-forw) 5’ggC TAC TgC CCC ACC ATg ACC 3’  66,5 
Reverse Primer (bhCG-rev) 5’ ggA CTC gAA gCg CAC ATC 3’  63 
Probe (TaqMan/Hydrolyse Probe: BhCG-
hydro) 
5’ FAM- CCT gCC TCA ggT ggT gTg CAA CTA C-
BHQ  3’  
69,5 
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HLA-G-assay: 
 
         Forward: HLAG-ex3 →    Exon 3   Exon 4 
5’  CTg gAg AAC ggg AAg gAg ATg CTg CAg CgC gCg gAC CCC CCC AAg  
 
 
 Universal probe #77    Reverse: HLAG-ex4rev 
ACA CAC gTg ACC CAC CAC CCT gTC TTT gAC TAT gAg gCC ACC CTg  3’ 
 
HLA-G ASSAY Tm value 
(˚C) 
Forward Primer (HLAG-ex3)    5’ CTg gAg AAC ggg AAg gAg AT 3’  60 
Reverse Primer (HLAG-ex4rev) 5’ CAg ggT ggC CTC ATA gTC AAA 3’  59 
Probe (Roche’s Universial probe 
#77) 
5’ FAM-C TTT gAC TAT gAg gCC ACC C -
BHQ  3’  
 
 
 
 
 
CRH assay: 
         Forward: CRH →  TaqMan/hydrolyse probe (FAM): CRH-hydro 
5’gAgCCTCCCATCTCCCTggATCTCACCTTCCACCTCCTCCgggAAgTCTTggAAATggCCAgggCCgAgCAgTTAg 
 Reverse: CRH 
CACAgCAAgCTCACAgC 3’ 
 
CRH ASSAY Tm value 
(˚C) 
Forward Primer (CRH-
forw)     
5’ gCC TCC CAT CTC CCT ggA T 3’ 60 
Reverse Primer  (CRH-
rev) 
5’ TgT gAg CTT gCT gTg CTA ACT g 3’ 59 
Probe (CRH-hydro) 5’ FAM-TCC TCC ggg AAg TCT Tgg AAA Tgg C-
BHQ 3’ 
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